Children's Intensive Care Drug Directory (CIDD) [ktd]

1st Edition



We pay our respects to the Aboriginal and Torres Strait Islander ancestors and custodians of this land, their spirits and their legacy.

The foundations laid by these ancestors—First Nations peoples gives strength, inspiration and courage to current and future generations.

We are committed to working towards a stronger and healthier Queensland community for Aboriginal and Torres Strait Islander and non-Aboriginal and Torres Strait Islander people.

CHQ-GDL-69000 Children's Intensive Care Drug Directory (CIDD) 1st Edition

Published by the State of Queensland (Queensland Health), August 2022

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence. To view a copy of this licence, visit https://creativecommons.org/licenses/by-nc-nd/4.0/

© Children's Health Queensland Hospital and Health Service, 2022.

You may use the work in unadapted form only, for noncommercial purposes only, as long as you attribute the State of Queensland (Queensland Health).

Cover artwork produced for Queensland Health by Gilimbaa. The motifs used represent the important network of people from Queensland communities and how they work together to empower Aboriginal and Torres Strait Islander Queenslanders to have long, healthy, productive lives.

Content Enquiries/Feedback:

Email the CIDD team at: CIDD@health.qld.gov.au

For further enquiries during business hours, call the Queensland Children's Hospital (QCH) Pharmacy: 0436 694 996

Printing of this document is not recommended for version control.

Disclaimer

The content presented in this publication is distributed by the Queensland Government including Children's Health Queensland as an information source only. The State of Queensland including Children's Health Queensland make no statements, representations or warranties about the accuracy, completeness or reliability of any information contained in this publication. The State of Queensland including Children's Health Queensland disclaims all responsibility and all liability including without limitation for liability in negligence for all expenses, losses, damages and costs you might incur as a result of the information being inaccurate or incomplete in any way, and for any reason reliance was placed on such information.

This book has been designed as a cognitive aid to guide best-practice and safe drug administration for any child admitted to an intensive care unit throughout Queensland. We recommend hospitals follow their usual practice for endorsement locally including presenting it to their local Medicines Advisory Committee (or equivalent) prior to use. It is designed to be used by staff with expertise and skills in the management of critically unwell children. We recommend staff become familiar with and receive training in the use of this book prior to using it. Whilst the information contained herein has gone through a vigorous checking and referencing process it is not a substitute for thinking and checking.

Clinical incidents, risks and near misses should be reported through local HHS clinical incident reporting mechanisms. We encourage local HHSs to report CIDD feedback and concerns via email: CIDD@health.qld.gov.au

Purpose

The Children's Intensive Care Drug Directory (CIDD) pronounced 'kid', is a medication infusion guide for managing critically unwell children in an intensive care setting that was sponsored by the Queensland Paediatric Critical Care Pathway Project (QPCCP) in 2021.

CIDD includes continuous infusion medications used in paediatric critical care, as determined by the CIDD working group and steering committee in 2021.

CIDD is designed for use 'at the bedside' by critical care nursing staff who prepare and administer continuous infusions to paediatric patients.

CIDD contains evidence-based and clearly referenced medicines information and is intended to reduce unwarranted variation in medication preparation and administration in paediatric critical care across Queensland Health.

CIDD aligns with international safety standards for 'best practice' critical care, by promoting the use of standardisedconcentration infusions used in conjunction with Dose Error Reduction Software (DERS) on intravenous 'smart pumps'. CIDD will provide a standardised, evidence based reference where sites can further develop, review and align their paediatric 'smart pump'/DERS libraries, critical care electronic prescribing tools and local medication guidelines.

Aim

CIDD has been developed by a multidisciplinary team of Queensland Health (QH) clinicians with emergency, paediatric, and paediatric and/or adult intensive care expertise.

CIDD provides a user-friendly resource, to reduce the cognitive burden for clinicians administering continuous infusions to critically unwell children.

CIDD provides a concise guide to infusion preparation, concentration, choice of infusion device, 'usual' dose range as well as 'max dose' (listed separately), compatible fluids and critical notes or special considerations.

CIDD will help you 'tie' all those critical care threads together.



Considerations

CIDD is not a substitute for clinically appropriate, carefully checked medication infusions. The content should be used by staff with expertise and skills in the management of critically unwell children. It is designed to be used in conjunction with state and/or local resources which contain information on medicine indication, specific dose, interactions, complex medicine compatibilities, precautions and potential side effects.

Direct links to selected statewide paediatric guidelines have been embedded within CIDD. For example, guidelines for complex or highly specialised medications such as those used in metabolic disease.

To seek further information from Children's Health Queensland (CHQ) Hospital and Health Service (HHS) about access to pre-printed medication infusion labels for use in critical care environments, clinicians can email: <u>CHQMedicationSafety@health.qld.gov.au</u>.

Every effort has been made to align CIDD with the current Queensland Children's Hospital (QCH) Metavision[®] 'Tips and Tricks' and the infusions described in CHQ Paediatric Intensive Care DERS Profile. The information in CIDD reflects current available evidence and is subject to change. For references and explanations of consensus decisions, go to the supplemental information at the end of the resource.

CIDD – Putting it to use

CIDD provides a list of standard infusion concentrations suitable to be used in Queensland paediatric critical care units. The list was reviewed and agreed by the 2021 CIDD working group.

Prerequisite check:

The CIDD Steering Committee and the Queensland Paediatric Intensive Care Advisory Group (PICAG), advise all Hospital and Health Services (HHS) to **complete a safety check by** comparing the CIDD material with:

- local PICU/ICU guidelines
- local PICU/ICU DERS library
- local Metavision[®]

This **prerequisite check** is necessary for HHS/local ICUs endorsing the use of CIDD, as differences may exist between CIDD and the existing local guidelines, DERS library and Metavision[®] which would pose a safety issue.

Where the CIDD does not align with local resources, the CIDD Steering Committee and PICAG recommend HHSs update/review their local DERS libraries to align their DERS with both Metavision[®] and CIDD for continuous infusions.

To seek further information on DERS software please contact CHQ Medication Safety team at CHQMedicationSafety@health.qld.gov.au

'Smart pump' and Dose Error Reduction Software (DERS)

Smart intravenous infusion pumps, with Paediatric specific Dose Error Reduction Software (DERS) should be used for all paediatric patients.

The <u>NSQHS Medication Safety Standard 4</u> recommends ensuring that current and accurate medicines information and decision support tools are readily available to the clinical workforce for clinical decisions relating to medicine use (4.9) and that high-risk medicines are stored, prescribed, dispensed and administered safely (4.11).

Standard infusion concentrations are the gold standard for paediatric critical care, replacing the historical use of a 'weight-based dose in a standard fluid volume'. Paediatric DERS libraries should include all standard concentrations and additionally, a blank concentration for limited/selected medicines (see 'References to support medication recommendations' table, page 75–83).

In DERS language, a 'blank' concentration is defined as the ability to modify both the amount of medicine and the volume, to individualise a concentration. Blank concentrations are rarely required (e.g. severely fluid restricted patients or during significant medication shortages). Consult your pharmacist/published resources for information if preparing any infusion where 'blank' concentration will be used. Medical consultant approval is recommended for use of any blank concentration prior to infusion connection.

'Dose over time' medication



Not all medicines are listed in CIDD.

Emergency 'once only' and intermittent 'dose over time' medication administration is beyond the scope of this resource.

Clinicians should access existing references available via Clinical Knowledge Network (CKN) such as:

- Paediatric Injectable Guidelines (PIG)
- Australian Injectable Drugs Handbook (AIDH)
- <u>Australian Medicines Handbook Children's Dosing</u> <u>Companion (AMHc)</u>

In acute paediatric resuscitation situations, use the current version of the Children's Resuscitation <u>Emergency Drug</u> <u>Dosage (CREDD) guide</u>. CREDD can be accessed via the Queensland Paediatric Emergency Care webpage. Hardcopies are available to purchase.

Ask for help early!

When caring for critically unwell paediatric patients, ask for help early.

> Sites without an onsite paediatric critical care facility:

Call Retrieval Services Queensland (RSQ) on 1300 799 127

If required, Paediatric Critical Care specialists from your critical care referral site can guide clinicians through medicine preparation.

CIDD and **CREDD** – What's the difference?


CIDD and CREDD are complementary resources. Both are recommended for sites treating paediatric patients. Where possible, the infusion concentrations used for individual medicines have been standardised between CIDD and CREDD.

Children's Intensive Care Drug Directory (CIDD):

- Use in extended and ongoing paediatric critical care requiring infusion therapy.
- An aid to use standardised continuous medication infusions.
- Aids safe patient transfer to other sites, including to PICU centres.

Children's Resuscitation Emergency Drug Dosage (CREDD):

- Resuscitation of paediatric patients in the Emergency Department setting.
- Includes single doses, doses over time, and some medication infusion information.
- Weight based resource designed to ensure prompt medicine preparation and delivery.





How to use CIDD

CIDD has a landscape presentation with one line per standard concentration and is read from left to right *(example below)*. It is suitable for use in paediatric patients.

Medication:

- Medications are listed alphabetically by their generic name.
- For medications with multiple common names or where the DERS library lists under an 'indication + generic' name, an alphabetical name/place holder redirects the user to the required medicine, for example:
 - » Fat Emulsion for local anaesthetic toxicity See TOX Lipid 20% TOX (page 72)
 - » Vasopressin See Argipressin (page 16)
- *Italic descriptions* (below main medicine name) guide nursing staff as to when that specific profile may be most applicable.
- Where multiple concentrations for one medication exist, these are banded together down the left-hand side.

Infusion device:

- Syringe pump refers to standardised continuous infusions prepared in a syringe and delivered by a syringe pump.
- Large volume pump refers to standardised continuous infusions prepared in a fluid bag and delivered by a large volumetric pump.
- For infants, it is recommended that a syringe pump and the *Standard Concentration* is used to administer continuous infusions.

Final infusion concentration:

- The intended final concentration is shown both as the amount of medicine in the volume of fluid, and as a standardised concentration per unit volume.
- This concentration results when the preparation instructions are followed.

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
methADONe	methADONe	Syringe pump	100 mg/50 mL (2 mg/mL)	Dilute 100 mg to a total volume of 50 mL	Sodium Chloride 0.9%	0.01 to 0.1 mg/kg/hour Titrate to effect	 Specialist advice required BP, Cardiac and Respiratory rate monitoring <u>Reference</u>

Preparation:

- Details the amount of medicine required, and the total volume to dilute it to.
- When using an intravenous fluid bag, first consider if you need to remove/discard any fluid (e.g. remove a volume of fluid equivalent to the volume of medicine being added to the bag). For information on initial vial reconstitution, refer to product information.
- For medicines with no dilution, the solution is described as 'undiluted'.

Compatible fluids:

- Compatible base fluids for administration.
- **Preferred fluid** for administration is **bolded** (where appropriate).
- Lists are not exhaustive for all fluid combinations. If listed fluids are not available, check compatibility of the fluid before using or ask your referral site for advice.
- Medicine/fluid compatibility is included. Medicine/Medicine compatibility is not included, refer to QH medicines information resources via CKN.
- Consider use of Micromedex for IV compatibility check.

Usual dose range for critical care:

- Weigh the child to ensure a current weight is documented for all paediatric patients. Only in emergent situations where a child cannot be weighed should an estimate be used, with the child weighed as soon as practical (given inaccuracies of estimated weight).
- Clinical judgement regarding the dose prescribed is required when the weight is significantly above or below the normal weight for age and height (i.e. extremes of body weight). Consideration should include the actual weight, adjusted weight and ideal body weight and pharmacist consultation is required.
- The dose may require titration, on medical advice, to achieve clinical effect/target. When titrating medications in critically unwell paediatric patients escalate early if the required clinical effect is not obtained.
- Usual 'dose range' used in critical care. The dosing listed reflects available references and consensus of paediatric critical care consultants and may differ from the absolute maximum dose in published literature.
- Available, published, 'absolute' maximum doses are noted in a separate table and not included in the main table. Refer to "Reference" under special notes for a hyperlink to the position and appendix.

- Dosing units in this resource are the 'usual' dose units, used in paediatric critical care. Always confirm the dosing units required. When accepting a verbal or telephone instruction, ask for the prescribed dose to be spoken in full (e.g. start at '10 units per kilogram per hour' or 'start at 10 units per hour' rather than start at '10 units'). For safety, and to ensure unambiguous communication in a high risk situation, ask one person to receive the verbal instruction and document it, then use a second person read back of the documented order (including units) to the person who gave it, to confirm all verbal information.
- For some medicines, 'dose capping' at an adult dosage is applied.



- Specific preparation or administration advice
- Type of venous access required
- Monitoring required during infusion
- Extravasation considerations
- Links to specific CHQ procedures or statewide guidelines (where appropriate)

References

- See <u>Reference List</u> (page 84–86) for full list of references used in the CIDD.
- Maximum dose reported in literature (which may differ from the 'usual clinical' maximum dose commonly required) is also listed within the Reference section of CIDD.

Appendices

- <u>Appendix 1: Consensus Rationale</u> (page 87)
- <u>Appendix 2: Glossary</u> (page 88)
- Appendix 3: Blank Concentration Medicines (page 89)
- Appendix 4: Authors and Acknowledgements (page 90-91)



	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Acetylcysteine (N-Acetylcysteine) For use in NON-paracetamol related indications	Syringe pump	2,000 mg/50 mL (40 mg/mL)	Dilute 2,000 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%	4 mg/kg/hour	• <u>Reference</u>
	Acetylcysteine (N- Acetylcysteine)			Less than or equal 20 kg: Dilute 200 mg/kg to a total volume of 100 mL			• CHQ-PROC-01230
EINE (NAC)	<u>Step 1</u> For use in paracetamol toxicity	Large volume pump	Variable Refer to guideline for information on fluid restricted patients	More than 20 kg and less than 50 kg: Dilute 200 mg/kg to a total volume of 250 mL	Glucose 5%, Sodium Chloride 0.9%	200 mg/kg up to a maximum of 22,000 mg over 4 hours	Acetylcysteine <u>(Intravenous) for</u> <u>Paracetamol Poisoning</u> <u>Reference</u> CHQ-PROC-01230
ACETYLCYSTEINE (NAC)	To be used in conjunction with CHQ-PMG-01230			More than or equal 50 kg: Dilute 200 mg/kg to a total volume of 500 mL			
AC	Acetylcysteine (N-Acetylcysteine)			Less than or equal 20 kg: Dilute 100 mg/kg to a total volume of 250 mL			
	<u>Step 2</u> For use in paracetamol toxicity	Large volume pump	Variable Refer to guideline for information on fluid restricted patients	More than 20 kg and less than 50 kg: Dilute 100 mg/kg to a total volume of 500 mL	Glucose 5%, Sodium Chloride 0.9%	100 mg/kg up to a maximum of 11,000 mg over 16 hours	Acetylcysteine (Intravenous) for Paracetamol Poisoning
	To be used in conjunction with CHQ-PMG-01230			More than or equal 50 kg: Dilute 100 mg/kg to a total volume of 1,000 mL			• <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Adrenaline (Epinephrine) Standard concentration	Syringe pump	1 mg/50 mL (20 microg/mL)	Dilute 1 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%	0.05 to 0.2 microg/kg/min Titrate to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
EPINEPHRINE)	Adrenaline (Epinephrine) Consider for fluid restricted patients	Syringe pump	6 mg/50 mL (120 microg/mL)	Dilute 6 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%	0.05 to 0.2 microg/kg/min Titrate to effect	 Central access required BP and Cardiac monitoring Extravasation caution Reference
ADRENALINE (EPINEPHRINE)	Adrenaline (Epinephrine) Standard concentration	Large volume pump	6 mg/100 mL (60 microg/mL)	Dilute 6 mg to a total volume of 100 mL	Sodium Chloride 0.9%, Glucose 5%	0.05 to 0.2 microg/kg/min Titrate to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
	Adrenaline (Epinephrine) Consider for fluid restricted patients	Large volume pump	12 mg/100 mL (120 microg/mL)	Dilute 12 mg to a total volume of 100 mL	Sodium Chloride 0.9%, Glucose 5%	0.05 to 0.2 microg/kg/min Titrate to effect	 Central access required BP and Cardiac monitoring Extravasation caution Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Alprostadil	Syringe	100 microg/50 mL	Dilute 100 microg to a total volume of 50 mL	Glucose 5% , Sodium Chloride	To open duct: 50 to 100 nanog/kg/min	• Central access preferred • Kept in fridge
	(PGE1)	pump	pump (2 microg/mL)	Draw up diluent first to minimise contact of undiluted alprostadil with plastic	0.9%	To maintain open duct: 5 to 20 nanog/kg/min	 Monitor apnoea <u>Reference</u>
	Alteplase For patients with thromboembolism	Syringe pump	1 mg/mL	<u>CHQ-GDL-01403 Alteplase (rtPA)</u> Infusion for Thromboembolism Do not shake, swirl to reconstitute	_	0.5 mg/kg/hour for 6 hours (Maximum total infused dose = 100 mg/day)	BP monitoring <u>CHQ-GDL-01403</u> <u>Alteplase (rtPA) Infusion</u> <u>for Thromboembolism</u> <u>Reference</u>
ALTEPLASE	Апериазе	Syringe	1 mg/ml	CHQ-GDL-00734 Acute Arterial		Bolus: 0.09 mg/kg (up to 9 mg) over 1 minute	• BP monitoring • <u>CHQ-GDL-00734 Acute</u>
	For patients with ischaemic stroke	pump	1 mg/mL	<u>in Children</u> Do not shake, swirl to reconstitute		Infusion: 0.81 mg/kg (up to 81 mg) over 60 minutes (Maximum total dose 90 mg)	Arterial Ischaemic Stroke Management in Children • Reference

Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
Aminocaproic Acid	Syringe pump	1,000 mg/50 mL (20 mg/mL)	Dilute 1,000 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	10 to 30 mg/kg/hour (Maximum 30 gram/day)	 ECMO only Monitor Activated Clotting Time (ACT) <u>Reference</u>
amiNOPHYLLIne Ensure loading dose is given prior to commencing infusion	Syringe pump	250 mg/50 mL (5 mg/mL)	Dilute 250 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's Glucose 10%	Titrate according to serum concentrations (Maximum 1,139 mg/day unless guided by serum concentration) 1 month to 11 years: 1 mg/kg/hour 12 years or above: 0.5 to 0.7 mg/kg/hour	 Central access preferred Cardiac monitoring Therapeutic drug monitoring Extravasation caution Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
AROne	amiODAROne Less than 45 kg Standard concentration for patients less than 45 kg	Syringe pump	100 mg/50 mL (2 mg/mL)	Dilute 100 mg to a total volume of 50 mL Use non-PVC syringes and lines: if unavailable change infusion every 12 hours	Glucose 5%	Load: 5 to 6 mg/kg over 4 hours = 20 to 25 microg/kg/min for 4 hours (Maximum 300 mg) Maintenance: 5 to 15 microg/kg/min (Maximum 1,200 mg/day including loading dose)	 Central access preferred 0.22 micron in-line filter recommended BP and Cardiac monitoring Extravasation caution Reference
amIODAROne	amiODAROne Less than 45 kg Consider for fluid restricted patients less than 45 kg	Syringe pump	300 mg/50 mL (6 mg/mL)	Dilute 300 mg to a total volume of 50 mL Use non-PVC syringes and lines: if unavailable change infusion every 12 hours	Glucose 5%	Load: 5 to 6 mg/kg over 4 hours = 20 to 25 microg/kg/min for 4 hours (Maximum 300 mg) Maintenance: 5 to 15 microg/kg/min (Maximum 1,200 mg/day including loading dose)	 Central access required 0.22 micron in-line filter recommended BP and Cardiac monitoring Extravasation caution Reference
				amIODAROne – continued on next page	ge (page 15)		

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
ROne	amiODAROne 45 kg and above Standard concentration for patients 45 kg and above	Large volume pump	900 mg/450 mL (2 mg/mL)	Dilute 900 mg to a total volume of 450 mL Use a 500 mL bag Use non-PVC bags and giving sets: if unavailable change infusion every 12 hours	Glucose 5%	Load: 5 mg/kg over 4 hours (Maximum 300 mg) Maintenance: 37.5 mg/hour (Maximum 1,200 mg/day including loading dose)	 Central access preferred 0.22 micron in-line filter recommended BP and Cardiac monitoring Extravasation caution Reference
amlODAROne	amiODAROne 45 kg and above Alternative CREDD concentration	Large volume pump	500 mg/250 mL (2 mg/mL)	Dilute 500 mg to a total volume of 250 mL Use a 250 mL bag Use non-PVC bags and giving sets: if unavailable change infusion every 12 hours	Glucose 5%	Load: 5 mg/kg over 4 hours (Maximum 300 mg) Maintenance: 37.5 mg/hour (Maximum 1,200 mg/day including loading dose)	 Central access required 0.22 micron in-line filter recommended BP and Cardiac monitoring Extravasation caution Reference
Arginine (L-arginine) Ensure loading dose is given prior to commencing infusion		Large volume pump	6,300 mg/150 mL (42 mg/mL)	Dilute to 6,300 mg to a total volume of 150 mL	Glucose 10%, Glucose 5%, Sodium Chloride 0.9%	4 to 12.5 mg/kg/hour	 Metabolic Specialist advice required Central access preferred Observe for anaphylaxis Extravasation caution Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
ARGIPRESSIN (VASOPRESSIN)	Argipressin (Vasopressin) Less than 20 kg For hypotensive patients less than 20 kg	Syringe pump	10 units/50 mL (0.2 units/mL)	Dilute 10 units to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%	0.01 to 0.12 unit/kg/hour Titrate to effect	 Central access preferred Taper infusion slowly when discontinuing treatment BP and Cardiac monitoring Extravasation caution SAS Reference
	Argipressin (Vasopressin) 20 kg and above For hypotensive patients 20 kg and above	Syringe pump	20 units/50 mL (0.4 units/mL)	Dilute 20 units to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%	0.6 to 2.4 unit/hour Titrate to effect	 Central access preferred Taper infusion slowly when discontinuing treatment BP and Cardiac monitoring Extravasation caution SAS Reference
	Argipressin DI (Vasopressin) For patients with diabetes insipidus	Syringe pump	1 unit/50 mL (0.02 units/mL)	Dilute 1 unit to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%	0.001 to 0.003 unit/kg/hour Titrate in 0.001 unit/kg/hour increments at approximately 10-minute intervals to target urine output	 Central access preferred Taper infusion slowly when discontinuing treatment BP and Cardiac monitoring Extravasation caution SAS Reference
			Argipi	ressin (Vasopressin) – continued on n	ext page (page 17)		

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
ARGIPRESSIN (VASOPRESSIN)	Argipressin GI (Vasopressin) For patients with gastrointestinal haemorrhage	Syringe pump	50 units/50 mL (1 unit/mL)	Dilute 50 units to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%	0.12 to 0.3 unit/kg/hour Titrate to effect	 Central access preferred Taper infusion slowly when discontinuing treatment BP and Cardiac monitoring Extravasation caution SAS Reference
ARGIPRESSIN (Argipressin GI (Vasopressin) For patients with gastrointestinal haemorrhage	Large volume pump	100 units/100 mL (1 unit/mL)	Dilute 100 units to a total volume of 100 mL	Glucose 5%, Sodium Chloride 0.9%	0.12 to 0.3 unit/kg/hour Titrate to effect	 Central access preferred Taper infusion slowly when discontinuing treatment BP and Cardiac monitoring Extravasation caution SAS Reference
HEP SALINE	Arterial Heparinised	Syringe	100 units/50 mL	Draw up 100 units to a total volume of 50 mL	Sodium Chloride	1 to 2 mL/hour	Use syringe driver rather than pressure bag. Ensure bolus flushes are included
IAL HEF	Saline	pump	(2 units/mL)	Use pre-made bag if available	0.9%	Bolus flush: 1 to 2 mL	in fluid balance • <u>Reference</u>
ATROPINE	Atropine	Syringe pump	6 mg/20 mL (0.3 mg/mL)	Dilute 6 mg to a total volume of 20 mL	Sodium Chloride 0.9%	0.02 to 0.08 mg/kg/hour Titrate every 5 minutes according to response	Monitor heart rate <u>Reference</u>

Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes						
Benzoate/L-arginine – See	Senzoate/L-arginine – See Sodium Benzoate/L-arginine (page 67)											
Benzoate – See Sodium Be	enzoate – See Sodium Benzoate (page 66)											
Bicarbonate – See Sodium Bicarbonate (page 68)												
Bivalirudin	Syringe pump	250 mg/50 mL (5 mg/mL)	Dilute 250 mg to a total volume of 50 mL	Sodium Chloride 0.9%, Glucose 5%	0.05 to 0.25 mg/kg/hour Titrate every 3 to 4 hours to achieve target aPTT	 Haematologist advice required Monitor aPTT <u>Reference</u> 						
Calcium Chloride	Syringe pump	6.8 mmol/10 mL (0.68 mmol/mL)	Undiluted Draw up 6.8 mmol to a total volume of 10 mL		0.02 to 0.1 mmol/kg/hour Titrate to target calcium level	Central access required Monitor calcium level <u>Extravasation caution</u> <u>CHQ-PMG-01270</u> <u>Intravenous Calcium</u> <u>Reference</u>						

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
CALCIUM GUCONATE	Calcium Gluconate	Syringe pump	4.4 mmol/40 mL (0.11 mmol/mL)	Dilute 4.4 mmol to a total volume of 40 mL	Glucose 5% , Sodium Chloride 0.9%, Hartmann's	0.02 to 0.1 mmol/kg/hour Titrate to target calcium level	 Central access preferred Monitor calcium level Extravasation caution CHQ-PMG-01270 Intravenous Calcium Reference
CALCIUM C	Calcium Gluconate For patients undergoing plasma exchange	Large volume pump	4.4 mmol/100 mL (0.044 mmol/mL)	Dilute 4.4 mmol to a total volume of 100 mL	Sodium Chloride 0.9%, Glucose 5%, Hartmann's	0.044 mmol/kg/hour Titrate in increments of 0.022 mmol/kg/hour to target calcium level	 Central access preferred Extravasation caution CHQ-PMG-01270 Intravenous Calcium CHQ-GDL-14036 Management of patients recieiving Therapeutic Plasma Exchange (TPE) Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
CURIUM	Cisatracurium	Syringe pump	50 mg/50 mL (1 mg/mL)	Dilute 50 mg to a total volume of 50 mL	5% Glucose, Sodium Chloride 0.9%	1 to 4 microg/kg/min Titrate to effect every 5 to 10 minutes Target Train of Four 2/4 Bolus: 100 microg/kg	 Ventilatory support required Kept in fridge Train of Four monitoring [CHQ-WI-80106] Reversed by neostigmine <u>Reference</u>
CISATRACURIUM	Cisatracurium	Large volume pump	100 mg/100 mL (1 mg/mL)	Dilute 100 mg to a total volume of 100 mL	5% Glucose, Sodium Chloride 0.9%	1 to 4 microg/kg/min Titrate to effect every 5 to 10 minutes Target Train of Four 2/4 Bolus: 100 microg/kg	 Ventilatory support required Kept in fridge Train of Four monitoring [CHQ-WI-80106] Reversed by neostigmine <u>Reference</u>
	Clonidine	Syringe pump	300 microg/50 mL (6 microg/mL)	Dilute 300 microg to a total volume of 50 mL	Sodium Chloride 0.9%	0.5 to 2 microg/kg/hour Titrate to effect	 BP monitoring Taper infusion slowly when discontinuing treatment (rapid discontinuation may cause hypertensive crisis) Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Danaparoid Ensure loading dose is given prior to commencing infusion		750 units/50 mL (15 units/mL)	Dilute 750 units to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%	1.2 to 2 units/kg/hour Titrate to target antiXa levels	• Monitor antiXa • <u>Reference</u>
	Desferrioxamine	Syringe pump	2,000 mg/50 mL (40 mg/mL)	Dilute 2,000 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	15 mg/kg/hour; reduce rate after 4–6 hours (Maximum 80 mg/kg, up to 6 grams in 24 hours)	 BP monitoring Reduce infusion rate if hypotension occurs <u>Reference</u>
DEXMEDETOMIDINE	Dexmedetomidine	Syringe pump	200 microg/50 mL (4 microg/mL)	Dilute 200 microg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	0.2 to 1 microg/kg/hour Titrate to effect	 BP and Cardiac monitoring Avoid bolus, rapid administration may cause sinus arrest <u>Reference</u>
	Dexmedetomidine	Large volume pump	400 microg/100 mL (4 microg/mL)	Dilute 400 microg to a total volume of 100 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	0.2 to 1 microg/kg/hour Titrate to effect	 BP and Cardiac monitoring Avoid bolus, rapid administration may cause sinus arrest <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
DOBUTAMINE	Dobutamine Standard Concentration	Syringe pump	75 mg/50 mL (1.5 mg/mL)	Dilute 75 mg to a total volume 50 mL	Glucose 5%, Sodium Chloride 0.9%, Glucose 10%	2 to 10 microg/kg/min Titrate to effect every 2 to 3 minutes	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
	Dobutamine Consider for fluid restricted patients	Syringe pump	250 mg/50 mL (5 mg/mL)	Dilute 250 mg to a total volume 50 mL	Glucose 5%, Sodium Chloride 0.9%, Glucose 10%	2 to 10 microg/kg/min Titrate to effect every 2 to 3 minutes	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
	Dobutamine	Large volume pump	250 mg/100 mL (2.5 mg/mL)	Dilute 250 mg to a total volume 100 mL	Glucose 5%, Sodium Chloride 0.9%, Glucose 10%	2 to 10 microg/kg/min Titrate to effect every 2 to 3 minutes	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes			
DOPAMINE	Dopamine Standard concentration	Syringe pump	60 mg/50 mL (1.2 mg/mL)	Dilute 60 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	2 to 10 microg/kg/min Titrate in increments of 1 microg/kg/min every 10 minutes to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference 			
	Dopamine Consider for fluid restricted patients	Syringe pump	200 mg/50 mL (4 mg/mL)	Dilute 200 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	2 to 10 microg/kg/min Titrate in increments of 1 microg/kg/min every 10 minutes to effect	 Central access required BP and Cardiac monitoring Extravasation caution Reference 			
	Dopamine	Large volume pump	200 mg/100 mL (2 mg/mL)	Dilute 200 mg to a total volume of 100 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	2 to 10 microg/kg/min Titrate in increments of 1 microg/kg/min every 10 minutes to effect	Central access preferred BP and Cardiac monitoring Extravasation caution Reference			
Epinephrine – See Adrenaline (page 11)										

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
EPOPROSTENOL (FLOLAN®)	Epoprostenol (Flolan [®] brand) To be used in conjunction with CHQ-GDL-01027	Syringe pump	150 microg/50 mL (3 microg/mL)	Dilute 150 microg to a total volume of 50 mL **Complex preparation required – refer to PIG	Provided diluent only (glycine buffer)	Initial rate: 0.5 to 2 nanog/kg/min Titrate in increments of 0.5 to 2 nanog/kg/min every 15 minutes, up to 40 nanog/kg/min to achieve desired clinical effect	 Central line preferred Use 0.22 micron in-line filter BP monitoring Extravasation caution Taper infusion slowly when discontinuing treatment CHQ-GDL-01027 Epoprostenol Infusion for Pulmonary Arterial Hypertension Reference
EPOPROSTEN	Epoprostenol (Flolan [®] brand) To be used in conjunction with CHQ-GDL-01027	Syringe pump	500 microg/50 mL (10 microg/mL)	Dilute 500 microg to a total volume of 50 mL **Complex preparation required – refer to <u>PIG</u> **	Provided diluent only (glycine buffer)	Initial rate: 0.5 to 2 nanog/kg/min Titrate in increments of 0.5 to 2 nanog/kg/min every 15 minutes, up to 40 nanog/kg/min to achieve desired clinical effect	 Central line preferred Use 0.22 micron in-line filter BP monitoring Extravasation caution Taper infusion slowly when discontinuing treatment <u>CHQ-GDL-01027</u> Epoprostenol Infusion for Pulmonary Arterial Hypertension <u>Reference</u>
			Еро	prostenol (Flolan [®]) – <i>continued on ne</i> z	xt page (page 25)		

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
CHRONIC (FLOLAN®)	Epoprostenol Chronic (Flolan [®] brand) For use in patients with chronic pulmonary hypertension	Syringe pump	500 microg/50 mL (10 microg/mL)	Dilute 500 microg to a total volume of 50 mL **Complex preparation required – refer to <u>PIG</u> **	Provided diluent only (glycine buffer)	5 to 80 nanog/kg/min Titrate to effect	 Central line preferred Use 0.22 micron in-line filter BP monitoring Extravasation caution CHQ-GDL-01027 Epoprostenol Infusion for Pulmonary Arterial Hypertension Reference
EPOPROSTENOL C	Epoprostenol Chronic (Flolan® brand) For use in patients with chronic pulmonary hypertension	Large volume pump	1,000 microg/100 mL (10 microg/mL)	Dilute 1,000 microg to a total volume of 100 mL **Complex preparation required – refer to <u>PIG</u> **	Provided diluent only (glycine buffer)	5 to 80 nanog/kg/min Titrate to effect	 Central line preferred Use 0.22 micron in-line filter BP monitoring Extravasation caution CHQ-GDL-01027 Epoprostenol Infusion for Pulmonary Arterial Hypertension Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
EPOPROSTENOL (VELETRI®)	Epoprostenol (Veletri [®] brand) To be used in conjunction with CHQ-GUDL-01027	Syringe pump	150 microg/50 mL (3 microg/mL)	Dilute 150 microg to a total volume of 50 mL	Sodium Chloride 0.9%	Initial rate: 0.5 to 2 nanog/kg/min Titrate in increments of 0.5 to 2 nanog/kg/min every 15 minutes, up to 40 nanog/kg/min to achieve desired clinical effect	 Central line preferred Use 0.22 micron in-line filter BP monitoring Extravasation caution Taper infusion slowly when discontinuing treatment <u>CHQ-GDL-01027</u> <u>Epoprostenol Infusion</u> for Pulmonary Arterial <u>Hypertension</u> <u>Reference</u>
	Epoprostenol (Veletri® brand) To be used in conjunction with CHQ-GUDL-01027	Syringe pump	500 microg/50 mL (10 microg/mL)	Dilute 500 microg to a total volume of 50 mL	Sodium Chloride 0.9%	Initial rate: 0.5 to 2 nanog/kg/min Titrate in increments of 0.5 to 2 nanog/kg/min every 15 minutes, up to 40 nanog/kg/min to achieve desired clinical effect	 Central line preferred Use 0.22 micron in-line filter BP monitoring Extravasation caution Taper infusion slowly when discontinuing treatment CHQ-GDL-01027 Epoprostenol Infusion for Pulmonary Arterial Hypertension Reference

Epoprostenol Chronic (Veletri®) – *continued on next page (page 27)*

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
EPOPROSTENOL CHRONIC (VELETRI®)	Epoprostenol Chronic (Veletri [®] brand) For use in patients with chronic pulmonary hypertension	Syringe pump	500 microg/50 mL (10 microg/mL)	Dilute 500 microg to a total volume of 50 mL	Sodium Chloride 0.9%	5 to 80 nanog/kg/min Titrate to effect	 Central line preferred Use 0.22 micron in-line filter BP monitoring Extravasation caution CHQ-GDL-01027 Epoprostenol Infusion for Pulmonary Arterial Hypertension Reference
	Epoprostenol Chronic (Veletri® brand) For use in patients with chronic pulmonary hypertension	Large volume pump	1,000 microg/100 mL (10 microg/mL)	Dilute 1,000 microg to a total volume of 100 mL	Sodium Chloride 0.9%	5 to 80 nanog/kg/min Titrate to effect	 Central line preferred Use 0.22 micron in-line filter BP monitoring Extravasation caution CHQ-GDL-01027 Epoprostenol Infusion for Pulmonary Arterial Hypertension Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
JLOL	Esmolol	Syringe pump	500 mg/50 mL (10 mg/mL)	Undiluted Draw up 500 mg to a total volume of 50 mL		Initial rate: 25 to 100 microg/kg/min Titrate in increments of 25 to 50 microg/kg/min every 5 minutes to effect Bolus: 500 microg/kg	 BP and Cardiac monitoring Extravasation caution Taper infusion slowly when discontinuing treatment Reference
ESMOLOL	Esmolol Consider for patients 45 kg and above	Large volume pump	1,000 mg/100 mL (10 mg/mL)	Undiluted Draw up 1,000 mg to a total volume of 100 mL Use 100 mL empty bag or bottle		Initial rate: 25 to 100 microg/kg/min Titrate in increments of 25 to 50 microg/kg/min every 5 minutes to effect Bolus: 500 microg/kg	 BP and Cardiac monitoring Extravasation caution Taper infusion slowly when discontinuing treatment Reference
Ethacrynic Acid		Syringe pump	50 mg/50 mL (1 mg/mL)	Dilute 50 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	0.1 to 0.5 mg/kg/hour Titrate to effect	 BP and Electrolyte monitoring SAS <u>Reference</u>

Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes			
Ethanol 10% Ensure loading dose is given prior to commencing infusion	Large volume pump	50 mL/500 mL (10%)	Dilute 50 mL of ethanol 100% to a total volume of 500 mL	Glucose 5%	1 to 2 mL/kg/hour (Maximum 100 mL/hour)	 Central access required Ensure adequate mixing during preparation CNS and Respiratory monitoring Blood glucose monitoring Monitor serum ethanol level <u>Reference</u> 			
Fat Emulsion for local anaesthetic toxicity – See TOX Lipid 20% TOX (page 72)									

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Fentanyl Less than 35 kg	Syringe	500 microg/50 mL	Dilute 500 microg to	Glucose 5%,	0.5 to 5 microg/kg/hour Titrate to effect	Respiratory rate
	Standard concentration for patients less than 35 kg	pump	(10 microg/mL)	total volume of 50 mL	Sodium Chloride 0.9%	Bolus: 0.5 to 1 microg/kg	• <u>Reference</u>
	Fentanyl Less than 35 kg				Glucose 5%,	0.5 to 5 microg/kg/hour Titrate to effect	Respiratory rate
NγL	Consider for fluid restricted patients less than 35 kg	Syringe pump	1,000 microg/50 mL (20 microg/mL)	Dilute 1,000 microg to total volume of 50 mL	Sodium Chloride 0.9%	Bolus: 0.5 to 1 microg/kg	• <u>Reference</u>
FENTANYL	Fentanyl 35 kg and above	Syringe	1,000 microg/50 mL	Dilute 1,000 microg to	Glucose 5%,	25 to 200 microg/hour Titrate to effect	Respiratory rate monitoring
	Standard concentration for patients 35 kg and above	pump	(20 microg/mL)	total volume of 50mL	Sodium Chloride 0.9%	Bolus: 25 microg	• <u>Reference</u>
3: C re	Fentanyl 35 kg and above	Syringe 2,500 microg/50 ml pump (50 microg/mL)		Undiluted		25 to 200 microg/hour Titrate to effect	Respiratory rate
	Consider for fluid restricted patients 35 kg and above			Draw up 2,500 microg to a total volume of 50 mL	_	Bolus: 25 microg	monitoring • <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Flumazenil	Syringe pump	500 microg/20 mL (25 microg/mL)	Dilute 500 microg to a total volume of 20 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	2 to 10 microg/kg/hour (Maximum 500 microg/hour) Titrate to effect Bolus: 5 microg/kg (Maximum 200 microg)	 Monitor for seizures <u>Extravasation caution</u> <u>Reference</u>
	Fomepizole	Large volume pump	1,500 mg/500 mL (3 mg/mL)	Dilute 1,500 mg to a total volume of 500 mL If solidified, run the vial under warm water or hold in the hand until it forms a solution	Glucose 5% Sodium Chloride 0.9%	1 to 1.5 mg/kg/hour	• <u>Reference</u>
MIDE	Furosemide Standard concentration	Syringe pump	100 mg/50 mL (2 mg/mL)	Dilute 100 mg to a total volume of 50 mL	Sodium Chloride 0.9%, Hartmann's	0.05 to 0.5 mg/kg/hour Titrate to effect	 BP and Electrolyte monitoring <u>Reference</u>
FUROSEMIDE	Furosemide Consider for use in fluid restricted patients	Syringe pump	250 mg/50 mL (5 mg/mL)	Dilute 250 mg to a total volume of 50 mL	Sodium Chloride 0.9%, Hartmann's	0.05 to 0.5 mg/kg/hour Titrate to effect	 BP and Electrolyte monitoring <u>Reference</u>

Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
Glucagon For use in patients with hyperinsulinism	Syringe Pump	1 mg/50 mL (0.02 mg/mL)	Dilute 1 mg to a total volume of 50 mL	Glucose 5%	1 to 20 microg/kg/hour Titrate to effect	 Specialist advice required when used for toxicology indications Monitor closely for precipitation in the syringe <u>Reference</u>
Glucose 50%	Syringe Pump	25 g/50 mL (500 mg/mL)	Undiluted Draw up 25 gram to a total volume of 50 mL		3 to 12 mg/kg/min Titrate to target glucose level	Central access required Blood glucose monitoring <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
GLYCERYL TRINITRATE	Glyceryl Trinitrate Less than 45 kg <i>Standard</i> <i>concentration</i> <i>for patients</i> <i>less than 45 kg</i>	Syringe pump	50 mg/50 mL (1 mg/mL)	Dilute 50 mg to a total volume of 50 mL Use non-PVC syringe and lines if available	Glucose 5%, Sodium Chloride 0.9%	Initial rate: 0.2 microg/kg/min Titrate to effect in increments of 0.2 microg/kg/min every 3 to 5 minutes, up to 5 microg/kg/min	 Central access required BP and Cardiac monitoring Extravasation caution Reference
	Glyceryl Trinitrate Less than 45 kg Standard concentration for patients less than 45 kg	Large volume pump	100 mg/100 mL (1 mg/mL)	Dilute 100 mg to a total volume of 100 mL Use non-PVC bags and giving sets if available	Glucose 5%, Sodium Chloride 0.9%	Initial rate: 0.2 microg/kg/min Titrate to effect in increments of 0.2 microg/kg/min every 3 to 5 minutes, up to 5 microg/kg/min	 Central access required BP and Cardiac monitoring Extravasation caution Reference
	Glyceryl Trinitrate 45 kg and above Standard concentration for patients 45 kg and above	Syringe pump	50 mg/50 mL (1 mg/mL)	Dilute 50 mg to a total volume of 50 mL Use non-PVC syringe and lines if available	Glucose 5%, Sodium Chloride 0.9%	Initial rate: 5 to 10 microg/min Titrate to effect in increments of 5 microg/min every 3 to 5 minutes, up to 80 microg/min	 Central access required BP and Cardiac monitoring Extravasation caution Reference
	Glyceryl Trinitrate 45 kg and above Standard concentration for patients 45 kg and above	Large volume pump	200 mg/250 mL (0.8 mg/mL)	Dilute 200 mg to a total volume of 250 mL Use non-PVC bags and giving sets if available	Glucose 5%, Sodium Chloride 0.9%	Initial rate: 5 to 10 microg/min Titrate to effect in increments of 5 microg/min every 3 to 5 minutes, up to 80 microg/min	 Central access required BP and Cardiac monitoring Extravasation caution Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
HEPARIN	Heparin Standard concentration Check whether loading dose is required prior to commencing infusion	Syringe pump	5,000 units/50 mL (100 unit/mL)	Dilute 5,000 units to a total volume of 50 mL	Sodium Chloride 0.9%, Glucose 5%	Variable initial rate, refer to policy Usual range: 5 to 40 unit/kg/hour Titrate to target aPTT or antiXa every 4 to 6 hours	 Monitor aPTT or antiXa <u>CHQ-PMG-01200 Heparin</u> <u>Sodium (Unfractionated</u> <u>Heparin)</u> <u>Reference</u>
	Heparin Consider for fluid restricted patients Check whether loading dose is required prior to commencing infusion	Syringe pump	25,000 units/50 mL (500 unit/mL)	Dilute 25,000 units to a total volume of 50 mL Use pre-made syringe if available	Sodium Chloride 0.9%, Glucose 5%	Variable initial rate, refer to policy Usual range: 5 to 40 unit/kg/hour Titrate to target aPTT or antiXa every 4 to 6 hours	 Monitor aPTT or antiXa <u>CHQ-PMG-01200 Heparin</u> <u>Sodium (Unfractionated</u> <u>Heparin)</u> <u>Reference</u>
	Heparin ECLS For use in patients on ECLS	Syringe pump	5,000 units/50 mL (100 units/mL)	Dilute 5,000 units to a total volume of 50 mL	Sodium Chloride 0.9%, Glucose 5%	10 to 50 unit/kg/hour Titrate to target antiXa every 4 hours	 ECMO only – QCH Local Guideline Monitor antiXa <u>Reference</u>
			25,000 units/50 mL (500 units/mL)	Dilute 25,000 units to a total volume of 50 mL Use pre-made syringe if available			
Heparinised Saline for arterial lines – See Arterial Heparinised Saline (page 17)							
Heparinised Saline for pulmonary artery lines – See PA Heparinised Saline (page 56)							
Heparinised Saline for venous lines – See Venous Heparinised Saline (page 74)							

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
hydrALAZINe	hydrALAZINe	Syringe pump	20 mg/50 mL (0.4 mg/mL)	Dilute 20 mg to a total volume of 50 mL	Sodium Chloride 0.9%, Hartmann's	12.5 to 50 microg/kg/hour Titrate to effect	 BP and Cardiac monitoring <u>Extravasation caution</u> <u>Reference</u>
hydrAl	hydrALAZINe	Large volume pump	40 mg/100 mL (0.4 mg/mL)	Dilute 40 mg to a total volume of 100 mL	Sodium Chloride 0.9%, Hartmann's	12.5 to 50 microg/kg/hour Titrate to effect	 BP and Cardiac monitoring <u>Extravasation caution</u> <u>Reference</u>
HYDROmorphone	HYDROmorphone	one Syringe 10 mg/50 mL pump (0.2 mg/mL)	10 mg/50 mL	Dilute 10 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	Initial rate: 2 to 5 microg/kg/hour Titrate to effect up to 12 microg/kg/hour	 Respiratory rate monitoring BP monitoring <u>Reference</u>
HYDROm			(0.2 mg/mL)			Bolus: 1 microg/kg	
Hypertonic Saline – See Sodium Chloride 3% (page 69)							
INSULIN	Insulin (Actrapid®)	Syringe pump	50 units/50 mL (1 unit/mL)	Dilute 50 units to a total of 50 mL	Sodium Chloride 0.9%, Glucose 5%, Glucose 10%	0.05 to 0.1 unit/kg/hour	 Kept in fridge Blood glucose monitoring Electrolyte monitoring <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
ISOPRENALINE	Isoprenaline Less than 10 kg	Syringe pump	1 mg/50 mL (20 microg/mL)	Dilute 1 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Glucose 10%	0.05 to 0.5 microg/kg/min Titrate to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
	Isoprenaline 10 kg and above	Syringe pump	3 mg/50 mL (60 microg/mL)	Dilute 3 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Glucose 10%	0.5 to 10 microg/min Titrate to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
	Isoprenaline 10 kg and above	Large volume pump	6 mg/100 mL (60 microg/mL)	Dilute 6 mg to a total volume of 100 mL	Glucose 5%, Sodium Chloride 0.9%, Glucose 10%	0.5 to 10 microg/min Titrate to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
KETAMINE	Ketamine				Coduum (Chlorido	Analgesia: 1 to 5 microg/kg/min Titrate to effect	 Cardiac and Respiratory rate monitoring <u>Extravasation caution</u> <u>Reference</u>
	Less than 30 kg Standard concentration	Syringe pump	200 mg/50 mL (4 mg/mL)	Dilute 200 mg to a total of 50 mL		Sedation and Asthma: 1 to 20 microg/kg/min Titrate to effect	
						Bolus: 100 microg/kg	
	Ketamine – continued on next page (page 37)						

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Ketamine Less than 30 kg	Syringe pump	400 mg/50 mL (8 mg/mL)	Dilute 400 mg to a total of 50 mL	Glucose 5%, Sodium Chloride	Analgesia: 1 to 5 microg/kg/min Titrate to effect Sedation and Asthma: 1 to 20 microg/kg/min	 Cardiac and Respiratory rate monitoring Extravasation caution
	Consider for fluid restricted patients				0.9%	Titrate to effect Bolus: 100 microg/kg	• <u>Reference</u>
KETAMINE	Ketamine 30 kg and above Standard concentration	Syringe pump	200 mg/50 mL (4 mg/mL)	Dilute 200 mg to a total of 50 mL	Glucose 5%, Sodium Chloride 0.9%	Analgesia and Opioid Tolerance: 2 to 8 mg/hour Titrate to effect Sedation: 6 to 30 mg/hour Titrate to effect Bolus: 5 mg	 Cardiac and Respiratory rate monitoring <u>Extravasation caution</u> <u>Reference</u>
	Ketamine 30 kg and above Consider for fluid restricted patients	Syringe pump	400 mg/50 mL (8 mg/mL)	Dilute 400 mg to a total of 50 mL	Glucose 5%, Sodium Chloride 0.9%	Analgesia and Opioid Tolerance: 2 to 8 mg/hour Titrate to effect Sedation: 6 to 30 mg/hour Titrate to effect Bolus: 5 mg	 Cardiac and Respiratory rate monitoring Extravasation caution Reference
				Ketamine – continued on next page	(page 38)		

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Ketamine	Large	400 mg/100 mL	Dilute 400 mg to a	Glucose 5%,	Analgesia and Opioid Tolerance: 2 to 8 mg/hour Titrate to effect	Cardiac and Respiratory rate monitoring
	30 kg and above	volume pump	(4 mg/mL)	total of 100 mL	Sodium Chloride 0.9%	Sedation: 6 to 30 mg/hour Titrate to effect	Extravasation caution Reference
						Bolus: 5 mg	
KETAMINE	Ketamine STATUS For use in patients with refractory status epilepticus	Syringe pump	400 mg/50 mL (8 mg/mL)	Dilute 400 mg to a total of 50 mL	Sodium Chloride 0.9%, Glucose 5%	Initial bolus: 100 to 200 microg/kg Maintenance: commence at 10 microg/kg/min Every increment increase needs to be preceded by a bolus of 100 to 200 microg/kg Titrate in increments of 5 to 10 microg/kg/min	 Cardiac and Respiratory rate monitoring Extravasation caution CHQ-GDL-80028 Management of Refractory Status Epilepticus in Children Reference
	nine – See Arginine (p nine with Sodium Be		ee Sodium Benzoate/L	-arginine (page 67)		every 10 minutes to effect Bolus: 100 microg/kg	

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Labetalol	Syringe pump	100 mg/20 mL (5 mg/mL)	Undiluted Draw up 100 mg to a total volume of 20 mL	_	0.25 to 1 mg/kg/hour Titrate in increments of 0.1 to 0.25 mg/kg/hour every 15 minutes to effect Bolus:	 Central access preferred BP and Cardiac monitoring Taper infusion slowly when discontinuing treatment
LABETALOL	Labetalol	Large	500 mg/100 mL	Undiluted		0.25 mg/kg 0.25 to 1 mg/kg/hour Titrate in increments of 0.1 to 0.25 mg/kg/hour every 15 minutes to effect	Reference Central access preferred BP and Cardiac monitoring
	Consider for patients 70 kg and above	volume pump	(5 mg/mL)	Draw up 500 mg to a total volume of 100 mL	_	Bolus: 0.25 mg/kg	 Taper infusion slowly when discontinuing treatment <u>Reference</u>
LA HEP SALINE	LA Heparinised Saline For patients with left atrial line	Syringe pump	100 units/50 mL (2 units/mL)	Draw up 100 units to a total volume of 50 mL Use pre-made bag if available	Sodium Chloride 0.9%	1 to 2 mL/hour	• Use syringe driver rather than pressure bag
	Levocarnitine	Syringe pump	1,000 mg/50 mL (20 mg/mL)	Dilute 1,000 mg to a total volume of 50 mL	Glucose 10%, Glucose 5%, Sodium Chloride	Load: 50 to 100 mg/kg over 30 minutes	 Metabolic specialist advice required SAS
		punp	(20 mg/mc)		0.9%, Hartmann's	Maintenance: 4 mg/kg/hour	• <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
ENDAN	Levosimendan	Syringe pump	2.5 mg/50 mL (50 microg/mL)	Dilute 2.5 mg to a total volume of 50 mL Prepare total 24 hour dose	Glucose 5%	Load: 12.5 microg/kg over 10 minutes Maintenance: 0.2 microg/kg/min for 24 hours; dose may be reduced if not tolerated	 Central line preferred Kept in fridge BP and Cardiac monitoring SAS <u>CHQ-PMG-01459</u> Levosimendan <u>Reference</u>
LEVOSIMENDAN	Levosimendan Consider for patients 45 kg and above	Large volume pump	12.5 mg/250 mL (50 microg/mL)	Dilute 12.5 mg to a total volume of 250 mL	Glucose 5%	Load: 12.5 microg/kg over 10 minutes Maintenance: 0.2 microg/kg/min for 24 hours; dose may be reduced if not tolerated	 Central line preferred Kept in fridge BP and Cardiac monitoring SAS <u>CHQ-PMG-01459</u> Levosimendan <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
LIDOCAINE	Lidocaine (Lignocaine)	Syringe pump	200 mg/50 mL (4 mg/mL)	Dilute 200 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%	Arrhythmias: Load: 0.5 to 1 mg/kg over 2 minutes Maintenance: 0.6 to 3 mg/kg/hour <u>Refractory Status</u> <u>Epilepticus:</u> Load: 1 to 3 mg/kg over 2 minutes Maintenance: 1 to 6 mg/kg/hour	 BP and Cardiac monitoring ECG monitoring CHQ-GDL-01458 Common arrhythmias and their management in the PICU CHQ-GDL-80028 Refractory Status Epilepticus Management in Children Reference
LIOTHYRONINE	Liothyronine	Syringe pump	20 microg/50 mL (0.4 microg/mL)	Dilute 20 microg to total volume of 50 mL Use equal parts Sodium Chloride 0.9% and Albumin 4% for dilution	Sodium Chloride 0.9% and Albumin 4%	0.1 to 0.15 microg/kg/hour	 BP and Cardiac monitoring SAS <u>Reference</u>
Lipid	Emulsion for local a	anaesthetic	coxicity – See TOX Lip	id 20% TOX (page 72)			

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
epam		Syringe	4 mg/50 mL	Dilute 4 mg to a total volume of 50 mL	Glucose 5%,	25 to 50 microg/kg/hour Titrate to effect	 Specialist advice required Kept in fridge Midazolam is preferred due to propylene glycol accumulation
LORazepam	LORazepam	pump	(80 microg/mL)	Invert to mix, do not shake	Sodium Chloride 0.9%	Bolus: 50 microg/kg	 Respiratory rate monitoring <u>Extravasation caution</u> SAS <u>Reference</u>
M SULFATE	Magnesium Sulfate	Syringe pump	25 mmol/50 mL (0.5 mmol/mL)	Dilute 25 mmol to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	0.08 to 0.3 mmol/kg/hour	 BP monitoring Monitor serum magnesium <u>CHQ-PMG 01246</u> <u>Magnesium Sulfate</u> <u>Intravenous</u> <u>CHQ-GDL-80028</u> <u>Refractory Status</u> <u>Epilepticus Management</u> <u>in Children</u> <u>Reference</u>
MAGNESIUM SULFATE	Magnesium Sulfate Consider for patients 45 kg and above	Large volume pump	50 mmol/100 mL (0.5 mmol/mL)	Dilute 50 mmol to a total volume of 100 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	0.08 to 0.3 mmol/kg/hour	 BP monitoring Monitor serum magnesium <u>CHQ-PMG 01246</u> <u>Magnesium Sulfate</u> <u>Intravenous</u> <u>CHQ-GDL-80028</u> <u>Refractory Status</u> <u>Epilepticus Management</u> <u>in Children</u> <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
METARAMINOL	Metaraminol Standard concentration	Syringe pump	2 mg/50 mL (0.04 mg/mL)	Dilute 2 mg to a total volume of 50 mL Do NOT place prefilled syringes in pumps	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	0.05 to 0.5 microg/kg/min Titrate in increments of 0.05 microg/kg/min every 5 minutes to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
METAR	Metaraminol Consider for fluid restricted patients	Large volume pump	20 mg/100 mL (0.2 mg/mL)	Dilute 20 mg to a total volume of 100 mL Do NOT place prefilled syringes in pumps	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	0.05 to 0.5 microg/kg/min Titrate in increments of 0.05 microg/kg/min every 5 minutes to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
methADONe	methADONe	Syringe pump	100 mg/50 mL (2 mg/mL)	Dilute 100 mg to a total volume of 50 mL	Sodium Chloride 0.9%	0.01 to 0.1 mg/kg/hour Titrate to effect	 Specialist advice required BP, Cardiac and Respiratory rate monitoring <u>Reference</u>
INE BLUE	Methylene Blue (Methylthioninium)	Syringe pump	50 mg/50 mL (1 mg/mL)	Dilute 50 mg to a total volume of 50 mL	Glucose 5%	0.25 mg/kg/hour	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
METHYLENE	Methylene Blue (Methylthioninium)	Large volume pump	100 mg/100 mL (1 mg/mL)	Dilute 100 mg to a total volume of 100 mL	Glucose 5%	0.25 mg/kg/hour	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
					Glucose 5%	Load: 0.1 mg/kg up to a maximum of 5 mg; repeat every 5 minutes for a maximum of 3 doses	• BP and Cardiac
	Metoprolol	Syringe pump	20 mg/50 mL (0.4 mg/mL)	Dilute 20 mg to a total volume of 50 mL	Sodium Chloride 0.9%	Maintenance: 0.5 to 5 microg/kg/min	• ECG monitoring
						Titrate in increments of 0.5 microg/kg/min every 30 minutes to effect	• <u>Reference</u>
METOPROLOL						(Maximum 110 microg/min)	
METOP	Metoprolol	Lorro			Glucose 5%,	Load: 0.1 mg/kg up to a maximum of 5 mg; repeat every 5 minutes for a maximum of 3 doses	• BP and Cardiac
	Consider for patients 45 kg and above	Large volume pump	40 mg/100 mL (0.4 mg/mL)	Dilute 40 mg to a total volume of 100 mL	Sodium Chloride 0.9%	Maintenance: 0.5 to 5 microg/kg/min	monitoringECG monitoringReference
						Titrate in increments of 0.5 microg/kg/min every 30 minutes to effect	
						(Maximum 110 microg/min)	

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Midazolam Standard concentration	Syringe pump	10 mg/50 mL (0.2 mg/mL)	Dilute 10 mg to a total volume of 50 mL	Glucose 5% , Sodium Chloride 0.9%, Glucose 10%	Less than 6 months: 10 to 60 microg/kg/hour; titrate to effect 6 months or above: 10 to 120 microg/kg/hour; titrate to effect Bolus: 20 microg/kg	 BP and Respiratory rate monitoring <u>Extravasation caution</u> <u>Reference</u>
MIDAZOLAM	Midazolam Consider for fluid restricted patients	Syringe pump	50 mg/50 mL (1 mg/mL)	Dilute 50 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Glucose 10%	Less than 6 months: 10 to 60 microg/kg/hour; titrate to effect 6 months or above: 10 to 120 microg/kg/hour; titrate to effect Bolus: 20 microg/kg	 BP and Respiratory rate monitoring <u>Extravasation caution</u> <u>Reference</u>
	Midazolam 70 kg and above	Syringe pump	50 mg/50 mL (1 mg/mL)	Dilute 50 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Glucose 10%	1 to 8 mg/hour Titrate to effect Bolus: 1 mg	 BP and Respiratory rate monitoring <u>Extravasation caution</u> <u>Reference</u>
				Midazolam – continued on next page	e (page 46)		

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Midazolam	Large volume	100 mg/100 mL	Dilute 100 mg to a	Glucose 5%, Sodium Chloride	1 to 8 mg/hour Titrate to effect	 BP and Respiratory rate monitoring
	70 kg and above	pump	(1 mg/mL)	total volume of 100 mL	0.9%, Glucose 10%	Bolus: 1 mg	<u>Extravasation caution</u> <u>Reference</u>
DLAM	Midazolam STATUS	Syringe	60 mg/50 mL	Dilute 60 mg to a	Sodium Chloride 0.9%,	100 to 400 microg/kg/hour Titrate in increments of 100 microg/kg/hour every 5 minutes to effect	 BP and Respiratory rate monitoring <u>Extravasation caution</u> <u>CHQ-GDL-80028</u>
MIDAZOLAM	Standard concentration	pump	(1.2 mg/mL)	total volume of 50 mL	Glucose 5%, Glucose 10%	Bolus: 100 microg/kg	Refractory Status Epilepticus Management in Children • Reference
	Midazolam STATUS	Large	250 mg/100 mL	Dilute 250 mg to a	Sodium Chloride 0.9%,	100 to 400 microg/kg/hour Titrate in increments of 100 microg/kg/hour every 5 minutes to effect	 BP and Respiratory rate monitoring <u>Extravasation caution</u> <u>CHQ-GDL-80028</u>
	Consider for fluid restricted patients	volume pump	(2.5 mg/mL)	total volume of 100 mL	Glucose 5%, Glucose 10%	Bolus: 100 microg/kg	Refractory Status Epilepticus Management in Children • Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Milrinone Standard concentration	Syringe pump	10 mg/50 mL (0.2 mg/mL)	Dilute 10 mg to a total volume of 50 mL	Glucose 5% , Sodium Chloride 0.9%, Hartmann's	0.2 to 0.75 microg/kg/min Titrate to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
MILRINONE	Milrinone Consider for fluid restricted patients	Syringe pump	20 mg/50 mL (0.4 mg/mL)	Dilute 20 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	0.2 to 0.75 microg/kg/min Titrate to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
	Milrinone	Large volume pump	20 mg/100 mL (0.2 mg/mL)	Dilute 20 mg to a total volume of 100 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	0.2 to 0.75 microg/kg/min Titrate to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Morphine	Syringe	5 mg/50 mL	Dilute 5 mg to a	Glucose 5%, Sodium Chloride	5 to 60 microg/kg/hour Titrate to effect	• Respiratory rate monitoring
	Standard concentration	pump	(0.1 mg/mL)	total volume of 50 mL	0.9%	Bolus: 20 microg/kg	• <u>Reference</u>
MORPHINE	Morphine	Syringe	30 mg/50 mL	Dilute 30 mg to a	Glucose 5% , Sodium Chloride	5 to 60 microg/kg/hour Titrate to effect	• Respiratory rate monitoring
MOR	Consider for fluid restricted patients	pump	(0.6 mg/mL)	total volume of 50 mL	0.9%	Bolus: 20 microg/kg	• <u>Reference</u>
	Morphine				Glucose 5%,	5 to 60 microg/kg/hour Titrate to effect	Respiratory rate
	Consider for fluid restricted patients on high doses	Syringe pump	50 mg/50 mL (1 mg/mL)	Dilute 50 mg to a total volume of 50 mL	Sodium Chloride 0.9%	Bolus: 20 microg/kg	 monitoring <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
Naloxone				Dilute 200 microg to a total of 50 mL	Glucose 5%, Sodium Chloride 0.9%	Opioid-induced itch: 0.5 to 2 microg/kg/hour Titrate in increments of 0.5 microg/kg/hour every 2 hours to effect	
		Syringe pump				Opioid overdose (full reversal): 10 to 40 microg/kg/hour Titrate to effect	 Monitor for opioid withdrawal <u>Reference</u>
						Bolus : 1 microg/kg	
	Nesiritide Standard			Dilute 150 microg to a total volume of 50 mL	Glucose 5%, Sodium Chloride	0.01 to 0.03 microg/kg/min Titrate in increments of	• BP monitoring • SAS
NESIRITIDE	concentration	pump	(o morog/me)	Do not shake, rotate vial gently to dissolve powder	0.9%	0.005 microg/kg/min every 3 hours to effect	• <u>Reference</u>
NESIF	Nesiritide	Syringe	1,500 microg/250 mL	Dilute 1,500 microg to a total volume of 250 mL	Glucose 5%, Sodium Chloride	0.01 to 0.03 microg/kg/min Titrate in increments of	• BP monitoring • SAS
	Consider for fluid restricted patients	pump	(6 microg/mL)	Do not shake, rotate vial gently to dissolve powder	0.9%	0.005 microg/kg/min every 3 hours to effect	• <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
lipine	niCARdipine	Syringe pump	10 mg/50 mL (0.2 mg/mL)	Dilute 10 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%	0.5 to 4 microg/kg/min up to maximum of 5 mg/hour Titrate in increments of 0.5 microg/kg/min every 15 minutes to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution SAS Reference
niCARdipine	niCARdipine	Large volume pump	20 mg/100 mL (0.2 mg/mL)	Dilute 20 mg to a total volume of 100 mL	Glucose 5%, Sodium Chloride 0.9%	0.5 to 4 microg/kg/min up to maximum of 5 mg/hour Titrate in increments of 0.5 microg/kg/min every 15 minutes to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution SAS Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
) Pine	niMODIPine 35 kg and less	Syringe pump	10 mg/50 mL (0.2 mg/mL)	Undiluted Draw up 10 mg to a total volume of 50 mL Use non-PVC syringe and lines if available Protect infusion from light	**Complex administration; refer to AIDH** Y-site only: Sodium Chloride 0.9%, Glucose 5%, Hartmann's	Initial rate: 15 microg/kg/hour If tolerated, increase after 2 hours to 30 microg/kg/hour	 Central access required BP monitoring Solution contains alcohol 23.7% (23.7 gram/100 mL) Reference
niMODIPine	niMODIPine 35 kg and less	Large volume pump	20 mg/100 mL (0.2 mg/mL)	Undiluted Draw up 20 mg to a total volume of 100 mL Use non-PVC tubing and empty bags Protect infusion from light	**Complex administration; refer to AIDH** Y-site only: Sodium Chloride 0.9%, Glucose 5%, Hartmann's	Initial rate: 15 microg/kg/hour If tolerated, increase after 2 hours to 30 microg/kg/hour	 Central access required BP monitoring Solution contains alcohol 23.7% (23.7 gram/100 mL) Reference
				niMODIPine – continued on next pag	ie (page 52)		

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
) Pine	niMODIPine Above 35 kg and less than 70 kg	Syringe pump	10 mg/50 mL (0.2 mg/mL)	Undiluted Draw up 10 mg to a total volume of 50 mL Use non-PVC syringe and lines if available Protect infusion from light	**Complex administration; refer to AIDH** Y-site only: Sodium Chloride 0.9%, Glucose 5%, Hartmann's	Initial rate: 0.5 mg/hour If tolerated, increase after 2 hours to 1 mg/hour	 Central access required BP monitoring Solution contains alcohol 23.7% (23.7 gram/100 mL) Reference
niMODIPine	niMODIPine Above 35 kg and less than 70 kg	Large volume pump	20 mg/100 mL (0.2 mg/mL)	Undiluted Draw up 20 mg to a total volume of 100 mL Use non-PVC tubing and empty bags Protect infusion from light	**Complex administration; refer to AIDH** Y-site only: Sodium Chloride 0.9%, Glucose 5%, Hartmann's	Initial rate: 0.5 mg/hour If tolerated, increase after 2 hours to 1 mg/hour	 Central access required BP monitoring Solution contains alcohol 23.7% (23.7 gram/100 mL) Reference
				niMODIPine – continued on next pag	ie (page 53)		

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
niMODIPine	niMODIPine 70 kg and above	Syringe pump	10 mg/50 mL (0.2 mg/mL)	Undiluted Draw up 10 mg to a total volume of 50 mL Use non-PVC syringe and lines if available Protect infusion from light	**Complex administration; refer to AIDH** Y-site only: Sodium Chloride 0.9%, Glucose 5%, Hartmann's	Initial rate: 1 mg/hour If tolerated, increase after 2 hours to 2 mg/hour	 Central access required BP monitoring Solution contains alcohol 23.7% (23.7 gram/100 mL) Reference
	niMODIPine 70 kg and above	Large volume pump	20 mg/100 mL (0.2 mg/mL)	Undiluted Draw up 20 mg to a total volume of 100 mL Use non-PVC tubing and empty bags Protect infusion from light	**Complex administration; refer to AIDH** Y-site only: Sodium Chloride 0.9%, Glucose 5%, Hartmann's	Initial rate: 1 mg/hour If tolerated, increase after 2 hours to 2 mg/hour	 Central access required BP monitoring Solution contains alcohol 23.7% (23.7 gram/100 mL) Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
NALINE	Noradrenaline (Norepinephrine) Standard concentration	Syringe pump	1 mg/50 mL (0.02 mg/mL)	Dilute 1 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%*	0.05 to 0.2 microg/kg/min Titrate to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
	Noradrenaline (Norepinephrine) Consider for fluid restricted patients	Syringe pump	4 mg/50 mL (0.08 mg/mL)	Dilute 4 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%*	0.05 to 0.2 microg/kg/min Titrate to effect	 Central access required BP and Cardiac monitoring Extravasation caution Reference
NORADRENALINE	Noradrenaline (Norepinephrine) Standard concentration	Large volume pump	4 mg/100 mL (0.04 mg/mL)	Dilute 4 mg to a total volume of 100 mL	Glucose 5%, Sodium Chloride 0.9%*	0.05 to 0.2 microg/kg/min Titrate to effect	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
	Noradrenaline (Norepinephrine) Consider for fluid restricted patients	Large volume pump	12 mg/100 mL (0.12 mg/mL)	Dilute 12 mg to a total volume of 100 mL	Glucose 5%, Sodium Chloride 0.9%*	0.05 to 0.2 microg/kg/min Titrate to effect	 Central access required BP and Cardiac monitoring Extravasation caution Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Octreotide	Syringe pump	500 microg/10 mL (50 microg/mL)	Dilute 500 microg to a total volume of 10 mL	Sodium Chloride 0.9%, Glucose 5%	Oesophageal varices and bleeding: 1 to 2 microg/kg/hour (Maximum 50 microg/hour) Chylothorax: 3 to 4 microg/kg/hour (Maximum 200 microg/hour) Titrate to effect	 Kept in fridge Blood glucose monitoring Taper infusion slowly when discontinuing treatment <u>Reference</u>
AZOLE	Omeprazole	Syringe pump	40 mg/50 mL (0.8 mg/mL)	Dilute 40 mg to a total volume of 50 mL <i>Replace infusion every 12 hours</i>	Sodium Chloride 0.9%, Glucose 5%	0.1 to 0.2 mg/kg/hour up to a maximum of 8 mg/hour	<u>Extravasation caution</u> <u>Reference</u>
OMEPRAZOLE	Omeprazole	Large volume pump	80 mg/100 mL (0.8 mg/mL)	Dilute 80 mg to a total volume of 100 mL Replace infusion every 12 hours	Sodium Chloride 0.9%, Glucose 5%	0.1 to 0.2 mg/kg/hour up to a maximum of 8 mg/hour	<u>Extravasation caution</u> <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	oxyCODONE	Syringe	10 mg/50 mL	Dilute 10 mg to a	Glucose 5%, Sodium Chloride	1 to 40 microg/kg/hour Titrate to effect	Pain specialist review required Respiratory rate
oxyCODONE	Standard concentration	pump	(0.2 mg/mL)	total volume of 50 mL	0.9%	Bolus : 20 microg/kg	• <u>Reference</u>
oxyCC	oxyCODONE	Syringe	50 mg/50 mL	Dilute 50 mg to a	Glucose 5%, Sodium Chloride	1 to 40 microg/kg/hour Titrate to effect	 Pain specialist review required Respiratory rate
	Consider for fluid restricted patients	pump	(1 mg/mL)	total volume of 50 mL	0.9%	Bolus: 20 microg/kg	• <u>Reference</u>
PA HEP SALINE	PA Heparinised Saline For patients with pulmonary artery line	Syringe pump	100 units/50 mL (2 units/mL)	Draw up 100 units to a total volume of 50 mL Use pre-made bag if available	Sodium Chloride 0.9%	1 to 2 mL/hour	• Use syringe driver rather than pressure bag
PANTOPRAZOLE	Pantoprazole	Syringe pump	40 mg/50 mL (0.8 mg/mL)	Dilute 40 mg to a total volume of 50 mL <i>Replace infusion every 12 hours</i>	Glucose 5%, Sodium Chloride 0.9%	0.1 to 0.2 mg/kg/hour up to a maximum of 8 mg/hour	<u>Extravasation caution</u> <u>Reference</u>
PANTOP	Pantoprazole	Large volume pump	80 mg/100 mL (0.8 mg/mL)	Dilute 80 mg to a total volume of 100 mL <i>Replace infusion every 12 hours</i>	Glucose 5%, Sodium Chloride 0.9%	0.1 to 0.2 mg/kg/hour up to a maximum of 8 mg/hour	Extravasation caution Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
PHENTOLAMINE	Phentolamine	Syringe pump	100 mg/50 mL (2 mg/mL)	Dilute 100 mg to a total volume of 50 mL	Sodium Chloride 0.9%	Initial rate: 5 to 10 microg/kg/min (<i>Maximum initial rate</i> 40 mg/hour) Titrate to effect	 BP and Cardiac monitoring SAS <u>Reference</u>
	Phentolamine Consider for patients 70 kg and above	Large volume pump	200 mg/100 mL (2 mg/mL)	Dilute 200 mg to a total volume of 100 mL	Sodium Chloride 0.9%	Initial rate: 5 to 10 microg/kg/min (<i>Maximum initial rate</i> 40 mg/hour) Titrate to effect	 BP and Cardiac monitoring SAS <u>Reference</u>
PHENYLEPHRINE	Phenylephrine	Syringe pump	10 mg/50 mL (0.2 mg/mL)	Dilute 10 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%	0.1 to 0.5 microg/kg/min Titrate to effect Bolus: 2 microg/kg	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference
PHENYLI	Phenylephrine	Large volume pump	20 mg/100 mL (0.2 mg/mL)	Dilute 20 mg to a total volume of 100 mL	Glucose 5%, Sodium Chloride 0.9%	0.1 to 0.5 microg/kg/min Titrate to effect Bolus: 2 microg/kg	 Central access preferred BP and Cardiac monitoring Extravasation caution Reference

Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
Phosphate (Sodium Dihydrogen Phosphate)	Syringe pump <i>OR</i>	Variable	Peripheral line: Dilute exact dose to 0.05 mmol/mL or weaker	Glucose 5%,	Initial rate: 0.05 mmol/kg/hour	 Electrolyte monitoring BP and Cardiac monitoring when infused at rate greater than
		Variable	Central line: Dilute exact dose to 0.12 mmol/mL or weaker	Sodium Chloride 0.9%	Titrate to target phosphate levels, up to a maximum of 0.2 mmol/kg/hour	at rate greater than 0.06 mmol/kg/hour • <u>Extravasation caution</u> • <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
CHLORIDE	Potassium Chloride Less than 50 kg High concentration	Syringe pump	20 mmol/20 mL (1 mmol/mL)	Undiluted Draw up 20 mmol to a total volume of 20 mL		0.1 to 0.3 mmol/kg/hour up to a maximum of 20 mmol/hour Titrate to target potassium levels	 Central access required Monitoring serum potassium BP and Cardiac monitoring Extravasation caution CHQ-PMG-01213 Potassium for Paediatric Patients – oral and intravenous Reference
POTASSIUM CHLORIDE	Potassium Chloride 50 kg and above High concentration	Syringe pump	40 mmol/40 mL (1 mmol/mL)	Undiluted Draw up 40 mmol to a total volume of 40 mL		0.1 to 0.3 mmol/kg/hour up to a maximum of 20 mmol/hour Titrate to target potassium levels	 Central access required Monitoring serum potassium BP and Cardiac monitoring Extravasation caution CHQ-PMG-01213 Potassium for Paediatric Patients – oral and intravenous Reference
			Ро	tassium Chloride – continued on next	page (page 60)		

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
HLORIDE	Potassium Chloride Standard concentration	Large volume pump	10 mmol/100 mL (0.1 mmol/mL)	Undiluted Use the 10 mmol potassium chloride in 100 mL sodium chloride 0.29% pre-made bag		0.1 to 0.3 mmol/kg/hour up to a maximum of 20 mmol/hour Titrate to target potassium levels	 BP and Cardiac monitoring Monitoring serum potassium Extravasation caution CHQ-PMG-01213 Potassium for Paediatric Patients – oral and intravenous Reference
POTASSIUM CHLORIDE	Potassium Chloride Consider for fluid restricted patients	Large volume pump	40 mmol/100 mL (0.4 mmol/mL)	Undiluted Use the 40 mmol potassium chloride in 100 mL sodium chloride 0.9% pre-made bag	_	0.1 to 0.3 mmol/kg/hour up to a maximum of 20 mmol/hour Titrate to target potassium levels	 Central access required Monitoring serum potassium BP and Cardiac monitoring Extravasation caution CHQ-PMG-01213 Potassium for Paediatric Patients – oral and intravenous Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Pralidoxime	Syringe	1,000 mg/50 mL	Dilute 1,000 mg to a	Sodium	Load: 15 mg/kg up to a maximum of 1,000 mg over 15 minutes	• Toxicologist advice required
PRALIDOXIME		pump (20 m	(20 mg/mL)	0 mg/mL) total volume of 50 mL	Chloride 0.9%	Maintenance: 10 mg/kg/hour up to a maximum of 250 mg/hour	• SAS • <u>Reference</u>
PRALI	Pralidoxime	Pralidoxime Large volume pump 2,000 mg/100 mL (20 mg/mL)	Dilute 2,000 mg to a total volume of 100 mL	Sodium Chloride 0.9%	Load: 15 mg/kg up to a maximum of 1,000 mg over 15 minutes	 Toxicologist advice required 	
					Maintenance: 10 mg/kg/hour up to a maximum of 250 mg/hour	• SAS • <u>Reference</u>	

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
		Syringe	200 mg/50 mL	Dilute 200 mg to a	Glucose 5%,	Load: 5 mg/kg up to a maximum of 100 mg over 10 minutes	• BP and Cardiac monitoring
IAMIDE	Procainamide	pump (4 mg/mL)	total volume of 50 mL	Sodium Chloride 0.9%	Maintenance: 20 to 80 microg/kg/min up to a maximum of 4,000 microg/min Titrate to effect	• SAS • <u>Reference</u>	
PROCAINAMIDE	Procainamide	Large volume pump (4 mg/mL)	1000 mg/250 mL	Dilute 1,000 mg to a	Glucose 5%,	Load: 5 mg/kg up to a maximum of 100 mg over 10 minutes	• BP and Cardiac monitoring
			total volume of 250 mL	Sodium Chloride 0.9%	Maintenance: 20 to 80 microg/kg/min up to a maximum of 4,000 microg/min Titrate to effect	• SAS • <u>Reference</u>	

DIODUFOI	Syringe 500 mg/50 pump (10 mg/ml	_	0.3 to 3 mg/kg/hour up to a maximum of 200 mg/hour Titrate to effect Bolus: 0.5 mg/kg Cumulative bolus and infusion dose must not exceed 4 mg/kg/hour	 BP, Cardiac and Respiratory rate monitoring <u>Reference</u>
od			exceed 4 mg/kg/hodi	
propOFol vol	Large volume pump (10 mg/ml		0.3 to 3 mg/kg/hour up to a maximum of 200 mg/hour Titrate to effect Bolus: 0.5 mg/kg Cumulative bolus and infusion dose must not exceed 4 mg/kg/hour	 BP, Cardiac and Respiratory rate monitoring <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Remifentanil Standard concentration	Syringe 2 m	2 mg/50 mL	Dilute 2 mg to a	Glucose 5%, Sodium Chloride 0.9%	0.05 to 0.3 microg/kg/min Titrate to effect	 BP, Cardiac and Respiratory rate monitoring Do not flush after
REMIFENTANIL		pump	(0.04 mg/mL)	total volume of 50 mL		Bolus: 0.1 microg/kg	administration as may cause respiratory depression • <u>Reference</u>
	Remifentanil Consider for fluid restricted patients	Syringe pump	5 mg/50 mL (0.1 mg/mL)	Dilute 5 mg to a total volume of 50 mL	Glucose 5% , Sodium Chloride 0.9%	0.05 to 0.3 microg/kg/min Titrate to effect	 BP, Cardiac and Respiratory rate monitoring Do not flush after
						Bolus: 0.1 microg/kg	administration as may cause respiratory depression • <u>Reference</u>
	Remifentanil	Large volume pump	20 mg/100 mL (0.2 mg/mL)	Dilute 20 mg to a total volume of 100 mL	Glucose 5%, Sodium Chloride 0.9%	0.05 to 0.3 microg/kg/min Titrate to effect	 BP, Cardiac and Respiratory rate monitoring Do not flush after
						Bolus : 0.1 microg/kg	administration as may cause respiratory depression • <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
ROCURONIUM	Rocuronium Standard concentration	Syringe pump	100 mg/50 mL (2 mg/mL)	Dilute 100 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	5 to 10 microg/kg/min Titrate to effect Target Train of Four 2 /4 Bolus: 100 microg/kg	 Kept in fridge Ventilatory support required Train of Four monitoring [CHQ-WI-80106] Reversed by sugammadex Extravasation caution Reference
ROCUR	Rocuronium Consider for fluid restricted patients	Syringe pump	250 mg/50 mL (5 mg/mL)	Dilute 250 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Hartmann's	5 to 10 microg/kg/min Titrate to effect Target Train of Four 2 /4 Bolus: 100 microg/kg	 Kept in fridge Ventilatory support required Train of Four monitoring [CHQ-WI-80106] Reversed by sugammadex Extravasation caution Reference

Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
Salbutamol	Syringe pump	50 mg/50 mL (1 mg/mL)	Undiluted Draw up 50 mg to a total volume of 50 mL		Load: 5 microg/kg/min for 20 minutes Maintenance: 1 to 2 microg/kg/min Titrate to effect	 Central line preferred BP and heart rate monitoring Blood glucose monitoring Monitor serum lactate and potassium CHQ-GDL-80112 Management of Severe Acute and Life- Threatening Asthma in PICU Reference
Sodium Benzoate Ensure loading dose is given prior to commencing infusion	Large volume pump	7,500 mg/150 mL (50 mg/mL)	Dilute 7,500 mg to a total volume of 150 mL	Glucose 10%, Glucose 5%	10.4 mg/kg/hour (usual maximum 12 gram/day)	Metabolic Specialist advice required Central access preferred Extravasation caution Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
SODIUM BENZOATE/L-ARGININE	Sodium Benzoate/ L-arginine Ensure loading dose is given prior to commencing infusion	Syringe pump	Sodium benzoate 50 mg/mL L-arginine 42 mg/mL	Dilute 2,500 mg of Sodium Benzoate, and 2,100 mg of L-arginine to a total volume of 50 mL **Complex administration; refer to Policy** Dose in DERS reflects Sodium Benzoate component	Glucose 10%	Sodium benzoate: 10.4 mg/kg/hour (usual maximum 12 gram/day) L-arginine: 8.75 mg/kg/hour (usual maximum 10 gram/day)	 Metabolic Specialist advice required Central access preferred Observe for anaphylaxis Extravasation caution CHQ-GDL-04313 Administration of Intravenous SODIUM BENZOATE and L-ARGININE HYDROCHLORIDE in children with hyperammonaemia associated with a urea cycle defect Reference
SODIUM BENZO	Sodium Benzoate/ L-arginine Ensure loading dose is given prior to commencing infusion	Large volume pump	Sodium benzoate 50 mg/mL L-arginine 42 mg/mL	Dilute 6,000 mg of Sodium Benzoate, and 5,040 mg of L-arginine to a total volume of 120 mL **Complex administration; refer to Policy** Dose in DERS reflects Sodium Benzoate component	Glucose 10%	Sodium benzoate: 10.4 mg/kg/hour (usual maximum 12 gram/day) L-arginine: 8.75 mg/kg/hour (usual maximum 10 gram/day)	 Metabolic Specialist advice required Central access preferred Observe for anaphylaxis Extravasation caution CHQ-GDL-04313 Administration of Intravenous SODIUM BENZOATE and L-ARGININE HYDROCHLORIDE in children with hyperammonaemia associated with a urea cycle defect Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Sodium Bicarbonate For ALL patients with peripheral access	Syringe pump	5 mmol/50 mL (0.1 mmol/mL)	Dilute 5 mmol to a total volume of 50 mL	Glucose 5% , Sodium Chloride 0.9%, Glucose 10%	0.25 to 1 mmol/kg/hour	 Peripheral line Electrolyte monitoring Extravasation caution Reference
BICARBONATE	Sodium Bicarbonate Less than 2 years	Syringe pump	25 mmol/50 mL (0.5 mmol/mL)	Dilute 25 mmol to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Glucose 10%	0.25 to 1 mmol/kg/hour	 Central access required Electrolyte monitoring Extravasation caution Reference
SODIUM BIC	Sodium Bicarbonate 2 years and above	Syringe pump	50 mmol/50 mL (1 mmol/mL)	Undiluted Draw up 50 mmol to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9%, Glucose 10%	0.25 to 1 mmol/kg/hour	 Central access required Electrolyte monitoring Extravasation caution Reference
	Sodium Bicarbonate 2 years and above	Large volume pump	100 mmol/100 mL (1 mmol/mL)	Undiluted Draw up 100 mmol to a total volume of 100 mL	Glucose 5%, Sodium Chloride 0.9%, Glucose 10%	0.25 to 1 mmol/kg/hour	 Central access required Electrolyte monitoring Extravasation caution Reference

Sodium Chloride 3% Syringe pump 25 mmol/50 mL (0.5 mmol/mL) Draw up 50 mL of sodium chloride 3% solution	Severe hyponatraemia: 0.05 to 0.25 mmol/kg/hour Titrate to target sodium level Rates over 0.25 mmol/kg/hour can be used for symptom management Following resolution of	Severe hyponatraemia: • Central access preferred • Monitor serum sodium level
Horizon Horizon Large Undiluted Sodium Chloride Large 125 mmol/250 mL Prepare 125 mmol in a	0.25 mmol/kg/hour can be used for symptom management	Central access preferred Monitor serum sodium
3% (0.5 mmol/mL) total volume of 250 mL Use pre-made bag	symptoms, maintenance infusion should not exceed 0.25 mmol/kg/hour ICP control: 0.05 to 0.5 mmol/kg/hour Titrate to target ICP For rapid control of ICP: 1 to 2.5 mmol/kg (= 2 to 5 mL/kg) over 10 to 20 minutes For refractory ICP: refer to sodium chloride 23.4%	<u>ICP control:</u> • Central access preferred • Monitor ICP and serum sodium level • CHO-GDL-80114

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
SODIUM nitroPRUSSide	Sodium nitroPRUSSide Standard concentration	Syringe pump	10 mg/50 mL (0.2 mg/mL)	Dilute 10 mg to a total volume of 50 mL Protect infusion from light	Glucose 5%	0.2 to 4 microg/kg/min Titrate to effect	 BP and Cardiac monitoring Monitor for cyanide toxicity <u>Extravasation caution</u> <u>Reference</u>
	Sodium nitroPRUSSide Consider for fluid restricted patients	Syringe pump	50 mg/50 mL (1 mg/mL)	Dilute 50 mg to a total volume of 50 mL Protect infusion from light	Glucose 5%	0.2 to 4 microg/kg/min Titrate to effect	 BP and Cardiac monitoring Monitor for cyanide toxicity Extravasation caution Reference
SODIUM THIOSULFATE	Sodium Thiosulfate For cyanide toxicity	Syringe pump	500 mg/50 mL (10 mg/mL)	Dilute 500 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride 0.9% ⁸	1 to 2.4 mg/kg/hour For treatment of sodium nitroprusside toxicity, infuse at 5 to 10 times the rate of sodium nitroprusside	 BP and Cardiac monitoring SAS <u>Reference</u>
	Sodium Thiosulfate To prevent cisplatin toxicity	Large volume pump	7,500 mg/100 mL (75 mg/mL)	Dilute 7,500 mg to a total volume of 100 mL	Glucose 5%, Sodium Chloride 0.9%	30 to 50 mg/kg/hour for 6 hours	 BP and Cardiac monitoring SAS <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
Sodium Valproate		Syringe	400 mg/50 mL	Dilute 400 mg to a	Glucose 5%, Sodium Chloride	Load: 40 mg/kg over 10 minutes	 Therapeutic drug monitoring Extravasation caution <u>CHQ-GDL-80028</u>
		pump (8 mg/m	(8 mg/mL)	.) total volume of 50 mL	0.9%	Maintenance: 1 to 3 mg/kg/hour Titrate to target serum concentration	Refractory Status Epilepticus Management in Children • Reference
TACrolimus		Large volume pump	2.5 mg/250 mL (10 microg/mL)	Dilute 2.5 mg to a total volume of 250 mL Use non-PVC and non-DEHP bags and giving sets	Sodium Chloride 0.9%, Glucose 5%	0.4 to 2 microg/kg/hour Titrate to target serum concentration	 Therapeutic drug monitoring <u>CHQ-PMG-01235</u> <u>Intravenous Tacrolimus</u> <u>Reference</u>
IHIOPENTONE)	Thiopental (Thiopentone)	(1)	470 mg/47 mL (10 mg/mL) 470 mg of thiopental	Dilute 470 mg to a	Glucose 5%,	1 to 8 mg/kg/hour Titrate to effect	Central access preferred BP and Cardiac monitoring <u>Extravasation caution</u>
THIOPENTAL (THIOPENTONE)		pump	is equivalent to 500 mg thiopental sodium	total volume of 47 mL	Sodium Chloride 0.9%	Bolus : 2 mg/kg	<u>CHQ-GDL-80028</u> <u>Refractory Status</u> <u>Epilepticus Management</u> <u>in Children</u> <u>Reference</u>

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
20% ТОХ	TOX Lipid 20% TOX (Fat Emulsion 20%) To be used in conjunction with Local Anaesthetic Systemic Toxicity Guideline	Syringe pump	20%	Undiluted Draw up a total volume of 50 mL		Load: 1.5 mL/kg Repeat every 5 minutes if required to maximum 3 doses Maintenance: 15 mL/kg/hour Maximum cumulative dose including boluses is 12 mL/kg	 Use 1.2 micron filter and filter extension sets <u>CHQ-GDL-00731 Local</u> <u>Anaesthetic Systemic</u> <u>Toxicity</u> <u>Reference</u>
TOX LIPID	TOX Lipid 20% TOX (Fat Emulsion 20%) To be used in conjunction with Local Anaesthetic Systemic Toxicity Guideline	Large volume pump	20%	Undiluted Use pre-made bag		Load: 1.5 mL/kg Repeat every 5 minutes if required to maximum 3 doses Maintenance: 15 mL/kg/hour Maximum cumulative dose including boluses is 12 mL/kg	 Use 1.2 micron filter and filter extension sets CHQ-GDL-00731 Local Anaesthetic Systemic Toxicity Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
	Tranexamic Acid	Syringe 1,000 mg/50 mL	Dilute 1,000 mg to a total volume of 50 mL	Glucose 5%, Sodium Chloride	Load: 10 mg/kg up to a maximum of 1,000 mg over 10 min	<u>CHQ-WI-80113 PICU:</u> Acute Bleeding Guideline <u>Reference</u>	
TRANEXAMIC ACID		pamp	pump (20 mg/mL) total volume of 50 mL	0.9%	Maintenance: 1.875 mg/kg/hour		
TRANEXA	Tranexamic Acid volume	Large volume		Dilute 2,000 mg to a total volume of 100 mL	Glucose 5% , Sodium Chloride 0.9%	Load: 10 mg/kg up to a maximum of 1,000 mg over 10 min	<u>CHQ-WI-80113 PICU:</u> <u>Acute Bleeding Guideline</u> <u>Reference</u>
		pump				Maintenance : 1.875 mg/kg/hour	
Triiod	lothyronine – See Lioi	thyronine (p	age 41)				
	Vancomycin	Syringe pump <i>OR</i> Large volume pump	Variable	Peripheral line : Dilute exact dose to 5 mg/mL or weaker Central line: Dilute exact dose to 10 mg/mL or weaker	Glucose 5%, Sodium Chloride 0.9%	Variable Titrate to target serum concentration	 Infectious Diseases specialist advice required Rapid infusion may cause red man syndrome Therapeutic drug monitoring Extravasation caution CHQ Vancomycin Therapeutic Drug Monitoring Reference

	Medication	Infusion device	Final infusion concentration	Preparation	Compatible fluids	Usual dose range	Special notes
Valpr	oate – See Sodium Val	proate (pag	ge 71)				
Vaso	pressin – See Argipres	sin (page 1	6)				
	Vecuronium	Syringe	50 mg/50 mL	Dilute 50 mg to a	Glucose 5%,	0.3 to 3 microg/kg/min Titrate to effect Target Train of Four 2 /4	 Ventilatory support required Train of Four monitoring [CHQ-WI-80106]
VECURONIUM	Less than 20 kg	pump (1 mg/mL)	total volume of 50 mL	Sodium Chloride 0.9%	Bolus: 100 microg/kg	 Reversed by sugammadex Extravasation caution Reference 	
		Syringe	Syringe 50 mg/50 mL Dilute 50 mg to a pump (1 mg/mL) total volume of 50 mL	Dilute 50 mg to a	Glucose 5%, Sodium Chloride 0.9%	0.5 to 5 mg/hour Titrate to effect Target Train of Four 2 /4	 Ventilatory support required Train of Four monitoring [CHQ-WI-80106]
		pump		total volume of 50 mL		Bolus : 2 to 4 mg	 Reversed by sugammadex Extravasation caution Reference
VENOUS HEP SALINE	Venous Heparinised	Syringe	100 units/50 mL	Draw up 100 units to a total volume of 50 mL	Sodium Chloride	1 to 2 mL/hour	 Use syringe driver rather than pressure bag. Ensure
	Saline		0.9%	Bolus flush: 1 to 2 mL	bolus flushes are included in fluid balance		

References to support medication recommendations

Medication	Usual maximum dose	Reference (refer to page 84–86)
Acetylcysteine	Step 1: 22,000 mg over 4 hours Step 2: 11,000 mg over 16 hours In massive overdose or on the advice of a toxicologist: 22,000 mg over 16 hours	1, 2, 10 <u>CHQ-PROC-01230 Acetylcysteine (Intravenous) for</u> <u>Paracetamol Poisoning</u>
	10 mg/kg/hour	7, 1, 2
Adrenaline Child	1 microg/kg/min Maximum 2 microg/kg/min at discretion of intensivist	5, 1, 2
Adrenaline Adolescent	40 microg/min	5, 1, 2
Alprostadil (PEG1)	400 nanog/kg/min	7, 1, 2, 6
Alteplase	100 mg/day	6, 5, 1, 2 <u>CHQ-GDL-01403 Alteplase (rtPA) Infusion for Thromboembolis</u>
Alteplase STROKE	Bolus: 9 mg Infusion: 81 mg Maximum total dose: 90 mg	5, 1, 2 <u>CHQ-GDL-00734 Acute Arterial Ischaemic Stroke Management</u> <u>in Children</u>
Aminocaproic Acid	30 g/day or 18 g/m²/day	5, 7, 2
amINOPHYLLIne	1,139 mg/day unless guided by serum concentrations	5, 6, 1, 2
amiODAROne	Load: 300 mg Maintenance: 900 mg/day Total dose over 24 hours: 1,200 mg	9, 6, 5, 4, 2, 1,
Arginine (L-arginine)	≤40 kg: 25 mg/kg/hour >40 kg: 21 mg/kg/hour	6, 1, 2
Argipressin DI	0.01 units/kg/hour	4, 5, 7, 1, 2

Medication	Usual maximum dose	Reference (refer to page 84–86)
Argipressin BP	0.48 unit/kg/hour	5, 7, 1, 2
Argipressin BP >20kg	6 unit/hour	5, 1, 2
Argipressin GI	1 unit/kg/hour	5, 6, 1, 2
Argipressin GI	48 unit/hour	5, 1, 2
Arterial Heparinised Saline		5
Atropine	2.4 mg/kg/hour	10
Bivalirudin	1.8 mg/kg/hour	13, 1, 2
Calcium Chloride	Usual maximum 0.34 mmol/kg/hour Rate up to 0.68 mmol/kg/hour may be required for citrated CVVH	5, 7, 1, 2 CHQ-PMG-01270 Intravenous Calcium
Calcium Gluconate	Usual max 0.34 mmol/kg/hour Rate up to 0.68 mmol/kg/hour may be required for citrated CVVH	5, 6, 7, 1, 2 <u>CHQ-PMG-01270 Intravenous Calcium</u>
Calcium Gluconate Plasma exchange	0.68 mmol/kg/hour	7 <u>CHQ-PMG-01270 Intravenous Calcium</u> <u>CHQ-GDL-14036 Management of patients recieiving</u> <u>Therapeutic Plasma Exchange (TPE)</u>
Cisatracurium	10 microg/kg/min	5, 7, 1, 2, 21, 55
Clonidine	3 microg/kg/hour	15, 16, 17
Danaparoid	7 unit/kg/hour	6, 18, 1, 2
Desferrioxamine	80 mg/kg in 24 hours, not to exceed 6 gram in 24 hours	4, 6, 1 ,2

Medication	Usual maximum dose	Reference (refer to page 84–86)
Dexmedetomidine	Usual max 1.5 microg/kg/hour Rates as high as 2.5 microg/kg/hour have been used	4, 5, 1 ,2
Dobutamine	20 microg/kg/min Maximum 30 microg/kg/min at discretion of intensivist	4, 5, 7, 1, 2
Dopamine	20 microg/kg/min Maximum 30 microg/kg/min at discretion of intensivist	6, 7, 1, 2
Epoprostenol (Flolan [®] brand)	80 nanog/kg/min	4, 5, 54 CHQ-GDL-01027 Epoprostenol Infusion for Pulmonary Arterial Hypertension
Epoprostenol Chronic (Flolan [®] brand)	195 nanog/kg/min	19 CHQ-GDL-01027 Epoprostenol Infusion for Pulmonary Arterial Hypertension
Epoprostenol (Veletri [®] brand)	80 nanog/kg/min	4, 5, 54 CHQ-GDL-01027 Epoprostenol Infusion for Pulmonary Arterial Hypertension
Epoprostenol Chronic (Veletri [®] brand)	195 nanog/kg/min	19 CHQ-GDL-01027 Epoprostenol Infusion for Pulmonary Arterial Hypertension
Esmolol	1,000 microg/kg/min	4, 5, 7
Ethacrynic Acid	0.8 mg/kg/hour	8, 5, 20
Ethanol 10%	100 mL/hour On haemodialysis: 4 mL/kg/hour (Maximum 200 mL/hour)	11, 1
Fentanyl	20 microg/kg/hour	5, 6, 7, 1, 2
Fentanyl >35kg	Usual maximum 300 microg/hour Rates as high as 700 microg/hour have been used	5, 1, 2
Flumazenil	10 microg/kg/hour (Maximum 500 mg/hour)	11,1 ,2

Medication	Usual maximum dose	Reference (refer to page 84–86)
Fomepizole	1.5 mg/kg/hour	7, 1
Furosemide	2 mg/kg/hour	4, 6,1, 2
Glucagon	50 microg/kg/hour For beta-blocker poisoning: 150 microg/kg/hour (Maximum 10 mg/hour) – consider alternative dilution	5, 6, 10, 1, 2
Glucose 50%	25 mg/kg/min	7, 1
Glyceryl Trinitrate	10 microg/kg/min Maximum 15 microg/kg/min at discretion of intensivist	6, 7, 1, 2, 8
Glyceryl Trinitrate >45kg	200 microg/min	5, 6, 7
Heparin	60 unit/kg/hour Refer to haematologist if the rate exceeds 40 unit/kg/hour	5, 1, 2 CHQ-PMG-01200 Heparin Sodium (Unfractionated Heparin)
Heparin ECLS	100 unit/kg/hour	6, 1, 2 CHQ ECLS manual and clinical guideline
hydrALAZINe	360 microg/kg/hour (Maximum 18,000 microg/hour)	6, 21, 1, 2
HYDROmorphone	160 microg/kg/hour	4, 5, 22, 1, 2
Insulin (Actrapid®)	0.2 unit/kg/hour	4, 7, 1, 2
Isoprenaline	2 microg/kg/min	5, 7, 1, 2, 21
Isoprenaline ≥10kg	Usual maximum 20 microg/min Rates as high as 30 microg/min have been used	5, 7, 1, 2, 21

Medication	Usual maximum dose	Reference (refer to page 84–86)
	Analgesia and opioid tolerance: Usual maximum 17 microg/kg/min	23, 24, 1, 2
	60 microg/kg/min	5, 1, 2
Ketamine	Refractory Status Epilepticus: 100 microgram/kg/min Rates as high as 167 microg/kg/min have been used	25 CHQ-GDL-80028 Management of Refractory Status Epilepticus in Children
	Metabolism of medications and pharmacokinetics are often different between children and adults. Therefore higher doses of Ketamine are require in children compared to adults	
Labetalol	Neonates: 4 mg/kg/hour Infants, children and adolescents: 3 mg/kg/hour	5, 6, 1, 2
Levocarnitine	12 mg/kg/hour	5, 6, 7, 1, 2
Levosimendan	0.3 microg/kg/min	8, 1, 2 <u>CHQ-PMG-01459 Levosimendan</u>
Lidocaine	Arrhythmias: 3 mg/kg/hour Refractory Status Epilepticus: 7 mg/kg/hour	 6, 7, 1,2 <u>CHQ-GDL-01458 Common arrhythmias and their management</u> in the PICU 5, 6, 7 <u>CHQ-GDL-80028 Refractory Status Epilepticus Management</u> in Children
Liothyronine	0.2 microg/kg/hour Rates as high as 0.6 microg/kg/hour have been used	5, 9, 26, 1, 2
LORazepam	Usual maximum 120 microg/kg/hour Rates as high as 330 microg/kg/hour have been used High doses increase the risk of propylene glycol toxicity: monitor closely	27, 28, 29, 7
Magnesium Sulfate	0.5 mmol/kg/hour	2, 6, 7 <u>CHQ-PMG 01246 Magnesium Sulfate Intravenous</u> <u>CHQ-GDL-80028 Refractory Status Epilepticus Management</u> <u>in Children</u>

Medication	Usual maximum dose	Reference (refer to page 84–86)
Metaraminol	5 microg/kg/min	8, 9, 1, 2
methADONe	Guided by palliative care consultant and/or intensivists For terminal illness: Highest rate at QCH 0.54 mg/kg/hour Highest rate documented in case reports: 2 mg/kg/hour	30, 31, 32
Methylene Blue	2 mg/kg/hour	9, 33, 1 2
Metoprolol	5 microg/kg/min (Maximum 110 microg/min)	6, 9, 34, 1, 2
Midazolam	300 mg/kg/hour	6, 7, 1, 2
Midazolam	20 mg/hour Maximum of 40 mg/hour at the discretion of the intensivist	5, 35, 36, 1, 2
Midazolam Status	Usual maximum 2,000 microg/kg/hour Rates as high as 3,000 microg/kg/hour have been used	7, 1, 2 <u>CHQ-GDL-80028 Management of Refractory Status</u> <u>Epilepticus in Children</u>
Milrinone	1 microg/kg/min Maximum 1.25 microg/kg/min at discretion of intensivist	4, 7, 1 ,2
Morphine	150 microg/kg/hour	7, 1,2
Morphine	20 mg/hour Maximum of 40 mg/hour at the discretion of the intensivist	50
Naloxone	Opioid-induced itch: 3 microg/kg/hour Opioid overdose (full reversal): Usual maximum 40 microg/kg/hour Rates as high as 160 microg/kg/hour have been used	5, 7, 1, 2
Nesiritide	Usual maximum 0.03 microg/kg/min Rates as high as 0.09 microg/kg/min have been used in ECMO (may be related to nesiritide incompatibility with heparin)	7, 37
niCARdipine	6 microg/kg/min (Maximum 15 mg/hour) Rates as high as 10 microg/kg/min (Maximum 15 mg/hour) have been used	5, 7, 1

Medication	Usual maximum dose	Reference (refer to page 84–86)
niMODIPine	30 microg/kg/hour (Maximum 2,000 microg)	6, 1, 21
Noradrenaline	1 microg/kg/min Maximum 2 microg/kg/min at discretion of intensivist	5, 1, 2
Noradrenaline	40 microg/min Maximum 100 microg/min at discretion of intensivist	
Octreotide	Oesophageal varices and bleeding: 2 microg/kg/hour (Maximum 50 microg/hour) Chylothorax: Usual maximum 10 microg/kg/hour (Maximum 200 microg/hour) Rates as high as 20 microg/kg/hour (Maximum 200 microg/hour) have been used	5, 6, 7, 52, 53
Omeprazole	0.2 mg/kg/hour (Maximum 8 mg/hour)	6, 1, 38, 39, 40
oxyCODONE	Rate guided by Acute Pain Service	www.rch.org.au/anaes/pain_management/Opioid_Infusion/
Pantoprazole	0.2 mg/kg/hour (Maximum 8 mg/hour)	41, 1 ,2 [extrapolation from adults, based on population pharmacokinetic study]
Phentolamine	50 microg/kg/min (Maximum 120 mg/hour) For phentolamine infusions we recommend caution to not exceed 40 mg/hour as an initial dose, which would be reached at a body weight of above 65 kg and 10 microg/kg/min infusion rate	5, 8, 9, 2
Phenylephrine	5 microg/kg/min (Maximum 180 microg/min) Rates as high as 15 microg/kg/min (Maximum 200 microg/min) have been used	5, 6, 7, 42, 2
Phosphate (Sodium Dihydrogen Phosphate)	0.2 mmol/kg/hour (Maximum 20 mmol/hour)	2, 6, 1
Potassium	0.5 mmol/kg/hour (Maximum 40 mmol/hour)	CHQ-PMG-01213 Potassium for Paediatric Patients – oral and intravenous
Pralidoxime	20 mg/kg/hour (Maximum 500 mg/hour)	7, 11, 1, 2
Procainamide	120 microg/kg/min (6 mg/min) Total of 2g per day	5, 7, 2, 8

Medication	Usual maximum dose	Reference (refer to page 84–86)
propOFol	Usual 4 mg/kg/hour (Maximum 300 mg/hour) Maximum 7 mg/kg/hour (Maximum 450 mg/hour) at discretion of intensivist Infusion durations over 48 hours or doses over 3mg/kg/hour increase the risk of propofol infusion syndrome	6, 7, 4, 1
Remifentanil	Usual 1 microg/kg/min Rates as high as 5 microg/kg/min have been used	1, 2, 9, 43, 44
Rocuronium	15 microg/kg/min	5, 6, 7, 9
Salbutamol	5 microg/kg/min	6, 1 <u>CHQ-GDL-80112 Management of Severe Acute and Life-</u> <u>Threatening Asthma in PICU</u>
Sodium Benzoate	20.8 mg/kg/hour (Maximum 12 gram/day)	12
Sodium Benzoate/ L-arginine	Sodium benzoate: 12 gram/day L-arginine: 12 gram/day	12 <u>CHQ-GDL-04313 Administration of Intravenous SODIUM</u> <u>BENZOATE and L-ARGININE HYDROCHLORIDE in children</u> with hyperammonaemia associated with a urea cycle defect
Sodium Bicarbonate	Usual 1 mmol/kg/hour Rates as high as 2 mmol/kg/hour has been used (when pH <6.9)	5, 7, 1, 2
Sodium Chloride 3%	Acutely symptomatic hyponatraemia: 1 mmol/kg/hour (Maximum 100 mL/hour) Non-symptomatic: 0.25 mmol/kg/hour	5, 7
Sodium Chloride 3%	2.4 mmol/kg/hour	7, 45, 46
Sodium nitroPRUSSide	4 microg/kg/min for infusion longer than 24 hours 10 microg/kg/min for infusion 10 minutes or less	6, 7, 1, 2
Sodium Thiosulfate	To prevent cyanide toxicity: 6 mg/kg/hour To prevent cisplatin toxicity: 2 gram/m2/hour (approx. 50 mg/kg/hour) for 5 to 12 hours	8, 10, 47, 5

Medication	Usual maximum dose	Reference (refer to page 84–86)
Sodium Valproate	6 mg/kg/hour	5, 7, 1, 2 <u>CHQ-GDL-80028 Refractory Status Epilepticus Management</u> <u>in Children</u>
TACrolimus	6.25 microg/kg/hour	7, 1, 2 CHQ-PMG-01235 Intravenous Tacrolimus
Thiopental	12 mg/kg/hour Rates as high as 55 mg/kg/hour have been used for Refractory Status Epilepticus	6, 7, 8, 1, 2 CHQ-GDL-80028 Refractory Status Epilepticus Management in Children
TOX Lipid 20% (Fat emulsion 20%)	30 mL/kg/hour Maximum cumulative dose of 12 mL/kg	48, 1 CHQ-GDL-00731 Local Anaesthetic Systemic Toxicity
Tranexamic Acid	10 mg/kg/hour	7 <u>CHQ-WI-80113 PICU: Acute Bleeding Guideline</u>
Vancomycin	Dose guided by vancomycin steady state serum concentrations (Aim 20 to 25 mg/L)	1,2 CHQ Vancomycin Therapeutic Drug Monitoring
Vecuronium	Usual 4.5 microg/kg/min Rates as high as 10 microg/kg/min have been used	7, 9, 49, 5, 1, 2
Vecuronium ≥20kg	10 mg/hour	5, 1, 2

Reference list

This document does not include the complete information, consult published references regarding duration of infusion and line changes.

- 1. Individual medicine monographs (2021) Australian Injectable Drugs Handbook (AIDH) via CKN. www.aidh.hcn.com.au (Accessed April-June 2021).
- 2. Individual medicine monographs (2021) Paediatric Injectable Guidelines (PIG) via CKN. https://pig.rch.org.au (Accessed April-June 2021).
- 3. Individual medicine monographs (2021) King Guide to Parenteral Admixtures. www.kingguide.com/ (Accessed April-June 2021).
- 4. Individual medicine monographs (2021) Australian Medicines Handbook Children's Dosing Companion (AMHc) via CKN. https://childrens.amh.net.au/ (Accessed April-June 2021).
- 5. Individual medicine monographs (2021) UptoDate (UTD) via CHQ. www.uptodate.com (Accessed April-June 2021).
- Individual medicine monographs (2021) British National Formulary for Children (BNFc) via CKN. https://medicinescomplete.com/#browse/bnfc via CKN (Accessed April-June 2021).
- 7. Individual medicine monographs (2021) Pediatric Injectable Drugs (The Teddy Bear Book) via CKN. https://medicinescomplete.com/#/browse/pid (Accessed April-June 2021).
- 8. Individual medicine monographs (2021) Micromedex via CKN. www.micromedexsolutions.com/micromedex2/librarian/ssl/true (Accessed April-June 2021).
- 9. Individual medicine monographs in Drug Doses 2017 (17th Edition) Frank Shann.
- 10. Individual medicine monographs (2021) TOXINZ Poisons Information via CKN. www.toxinz.com/Search (Accessed April-June 2021).
- 11. Individual medicines and therapeutics information (2021) Therapeutic Guidelines (eTG complete) via CKN. https://tgldcdp.tg.org.au/etgAccess (Accessed April-June 2021).
- 12. Häberle et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet Journal of Rare Diseases 2012; 7(32).
- 13. Buck M. Bivalirudin as an Alternative to Heparin for Anticoagulation in Infants and Children. JPPT 2015; 20(6): 408-417.
- 14. BabyBIG [Botulism Immune Globulin Intravenous (Human) (BIG-IV)] product information. Revised 10/2011.
- 15. Neubert et al. The CLOSED trial; CLOnidine compared with midazolam for SEDation of paediatric patients in the intensive care unit: study protocol for a multicentre randomised controlled trial. BMJ 2017; 7(6): e016031-e016031.
- 16. Hayden et al. Optimizing clonidine dosage for sedation in mechanically ventilated children: A pharmacokinetic simulation study. Pediatric Anesthesia 2019; 29: 1002-1010.
- 17. Wolf et al. Prospective multicentre randomised, double-blind, equivalence study comparing clonidine and midazolam as intravenous sedative agents in critically ill children: the SLEEPS (Safety profiLe, Efficacy and Equivalence in Paediatric intensive care Sedation) study. Health technology assessment 2014; 18(71): 1-242.
- 18. Vakil et al. Heparin-Induced Thrombocytopenia in the Pediatric Population: A review of Current Literature. J Pediatr Pharmacol Ther 2012; 17(1): 12-30.

- 19. Rosenzweig et al. Long-term Prostacyclin for Pulmonary Hypertension with Associated Congenital Heart Defects. Circulation. 1999; 99: 1858-1865.
- 20. Ricci et al. Furosemide versus ethacrynic acid in pediatric patients undergoing cardiac surgery: a randomized controlled trial. Critical Care (2015) 19:2-9.
- 21. Individual medicine monographs (2021) Australian Medicines Handbook (AMH) via CKN. https://amhonline.amh.net.au/ (Accessed April-June 2021).
- 22. Harkin et al. Conversion from Continuous Infusion Fentanyl to Continuous Infusion Hydromorphone in the Pediatric Intensive Care Unit. The Annals of Pharmacotherapy 2021-03-20; 1-8.
- 23. Schwenk et al. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med 2018; 43: 456–466.
- 24. Neunhoeffer et al. Ketamine Infusion as a Counter Measure for Opioid Tolerance in Mechanically Ventilated Children: A Pilot Study. Pediatr Drugs 2017; 19: 259–265.
- 25. Rosati et al. Ketamine for Refractory Status Epilepticus: A Systematic Review. CNS drugs 2018-11; 32 (11), 997-1009.
- 26. Huang et al. Severe Hypothyroidism Caused by Type 3 lodothyronine Deiodinase in Infantile Hemangiomas. N Engl J Med 2000; 343: 185-189.
- 27. Pediatric Sedation Outside of Operating Room, A Multispecialty International Collaboration. Second Edition. Keira P Mason, editor. Springer Science and Business Media New York 2015; Page 315.
- 28. Hansen et al. Development and Evaluation of a Guideline for Monitoring Propylene Glycol Toxicity in Pediatric Intensive Care Unit Patients Receiving Continuous Infusion Lorazepam. J Pediatr Pharmacol Ther 2015; 20(5): 367–372.
- 29. Chicella et al. Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients. Crit Care Med 2002; 30: 2752–2756.
- 30. Mott et al. Methadone for Analgesia in Children with Life-Limiting Illness: Experience from a Tertiary Children's Health Service. Children (Basel), 2018-07-01; 5(7), 86.
- 31. Gjedsted et al. Severe hypoglycemia during methadone escalation in an 8-year-old child. Acta anaesthesiologica Scandinavica, 2015; (11), 59(10): 1394-1396.
- 32. Habashy et al. Methadone for Pain Management in Children with Cancer. Paediatric drugs 2018;20(5):409-416.
- 33. Bitterman et al. Methylene Blue Administration for Distributive Shock States in Critically III Children. Isr Med Assoc J 2020; 22(7): 404-408.
- 34. Saqan et al. Evaluation of the safety and efficacy of metoprolol infusion for children and adolescents with hypertensive crises: a retrospective case series. Pediatr Nephrol 2017; 32: 2107–2113.
- 35. MacLaren et al. A Randomized, Double-Blind Pilot Study of Dexmedetomidine Versus Midazolam for Intensive Care Unit Sedation: Patient Recall of Their Experiences and Short-Term Psychological Outcomes. Journal of Intensive Care Medicine 2015;30(3): 167-175.
- 36. Ruokonen et al. Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. Intensive Care Med 2009; 35: 282–290.
- 37. Nesiritide (NATRECOR®) Product Information. Last revised December 2008.

- 38. Morris et al. A stability study of omeprazole diluted in sodium chloride for intravenous infusion and discussion regarding current practice in UK paediatric intensive care units. Archives of disease in childhood 2016;101(9): e2-e2.
- 39. Ashtekar CS, Vyas H, Stewart R, et al. Continuous intravenous infusion of omeprazole in the management of an upper gastrointestinal bleed in an infant. Paediatric and Perinatal Drug Therapy 2005; 5: 210–211.
- 40. Morgan et al. Intravenous Proton Pump Inhibitors in the Critical Care Setting. Critical care medicine 2002; 30(6 Suppl): S369-S372.
- 41. Pettersen et al. Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. British journal of clinical pharmacology 2009;67(2): 216-227.
- 42. United Kingdom Clinical Pharmacy Association. Critical Care Group. Minimum infusion volumes for fluid restricted critically ill patients. 4th edition 2012.
- 43. Buck M. Remifentanil Use in Infants and Children. Pediatric Pharmacotherapy 2013; 19 (5): 1-4.
- 44. Sammartino et al. Remifentanil in children. Pediatric anesthesia 2010;20(3):246-255.
- 45. Kochanek et al. Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines. Pediatr Crit Care Med 2019; 20: S1–S82.
- 46. Kochanek et al. Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Second Edition. Pediatr Crit Care Med 2012; 13: S1-S2.
- 47. GlobalRPh, The Clinician's Ultimate Reference. Nitroprusside. Accessed online 12 June 2021, https://globalrph.com/dilution/nitroprusside-nipride/
- 48. The Association of Anaesthetists of Great Britain & Ireland Safety Guideline. Management of Severe Local Anaesthetic Toxicity. 2010.
- 49. Johnson et al. Continuous-Infusion Neuromuscular Blocking Agents in Critically III Neonates and Children. Pharmacotherapy 2011; 31(6): 609–620.
- 50. Morphine Sulphate Medicines Information. London Health Sciences Centre Critical Care Trauma Centre. Last Updated September 20, 2018. Available online: www.lhsc.on.ca/ critical-care-trauma-centre/ morphine-sulfate.
- 51. Arroliga et al . Relationship of continuous infusion lorazepam to serum propylene. Crit Care Med 2004 Vol. 32, No. 8: 1709-1714.
- Glycol concentration in critically ill adults*
- 52. Saito et al. High Dose Octreotide for the Treatment of Chylothorax in Three Neonates. Neonatal Biol 2016, 5:2.
- 53. Helin et al Octreotide therapy for chylothorax in infants and children: A brief Review. Pediatr Crit Care Med 2006 Vol. 7, No. 6: 576-579.
- 54. Deep et al. Prostacyclin as an Anticoagulant for Continuous Renal Replacement Therapy in Children. Blood Purif 2017;43:279–289.
- 55. Burmester + Mok. Randomised controlled trial comparing cisatracurium and vecuronium infusions in a paediatric intensive care unit. Intensive Care Med (2005) 31:686–692.

Appendix 1: Consensus rationale

CIDD contains evidence-based and clearly referenced medicines information and is intended to reduce unwarranted variation in medication preparation and administration. Throughout CIDD, we have endeavoured to meet the preferences of all facilities providing care to critically unwell paediatric patients. For some medications, the following rationales are provided and have been discussed at length and endorsed with paediatric staff specialists, pharmacy, and nursing expertise.

Use of weight limits:

There is no clear guidance or evidence for when to change to an adult dosing regimen in paediatric patients. We recommend seeking advice from the pharmacist for largefor-age or large-for-height patients.

For some medications, we have decided to use a certain weight cut-off to avoid excessive dosages in larger patients; whereby usual adult dosing range would be exceeded if weight-based dosing regimens were continued to be used. Above this cut-off, adult dosing regimens should be used, (i.e. change from unit/kg/unit to unit/unit).

The medication infusions for which we have decided to do this for (in version one of CIDD) are **amiodarone**, **argipressin (vasopressin)**, **fentanyl**, **glyceryl trinitrate**, **isoprenaline**, **ketamine**, **midazolam and vecuronium**. Vice versa, we recommend using unit/kg/unit dosing as provided in CIDD for patients below the specified weight.

Propofol:

The recommended dose for propofol in children and adults are both dosed in mg/kg/hour and is therefore left in this dosing regimen.

Morphine:

For morphine we decided to not change to mg/hour, because for patients up to 100 kg bodyweight, the paediatric dosing would not exceed the usual adult dose range.

Inotropes and vasopressors:

Inotropes and vasopressors were deliberately left in paediatric dosage units, as the dose should be guided by the desired effect of the drug.

Neuro-muscular blockage:

In patients requiring continuous neuro-muscular paralysis with vecuronium or cisatracurium infusions we emphasise the use of Train of Four (TOF) monitoring. We recommend targeting two evoked muscular responses out of four peripheral nerve stimulations (2/4) as per QCH guidelines <u>CHQ-WI-80106</u>.

Appendix 2: Glossary

Term	Definition
Access (IV)	Intravenous (IV) cannulation is a technique in which a cannula is placed inside a vein to provide venous access. Allowing intravenous medication administration
ACT	Activated Clotting Time
anti-Xa	Test to monitor blood clotting in patients given anticoagulant therapy (e.g. low molecular weight heparin)
aPTT	Activated partial thromboplastin time - measure of clotting time
Blood pressure (BP)	Pressure of blood within the arteries in mmHg. Monitoring includes Systolic and Diastolic pressures.
Bolus	Single large dose of medicine, given at one time
Cardiac monitoring	Cardiac telemetry – ECG, heart rate, respiratory rate, oxygen saturation monitoring
Central access preferred	Preferred route of administration preferred is via large central vein
Central access required	Required route of administration required is via large central vein
DERS	Dose Error Reduction Software
ECG	Electrocardiogram
ECLS	Extracorporeal Life Support
ЕСМО	Extracorporeal Membrane Oxygenation
Extravasation	Leakage of medication/fluids from vein, into surrounding tissue. Can cause blistering, tissue sloughing or necrosis if fluid is vesicant
Glucose monitoring	Capillary blood analysed to show blood glucose level

Term	Definition
ICP	Intracranial pressure
In-line filter	Filter membrane on IV access line. Can prevent air or particles entering the venous circulation
Loading dose	Initial higher dose to rapidly attain a required medicine concentration
Large volume pump	Infusion pump capable of delivering large volume fluid/medicine infusions
Precipitation	Undesirable formation of an insoluble solid in an IV solution
Pressure bag	Device applied to an IV fluid bag - increases deliver rate
Special access scheme (SAS)	Scheme to access medications that are not licensed for use in Australia under the Australian Register of Therapeutic Goods
Respiratory monitoring	Respiratory rate, pattern and effort of breathing evaluation, Oxygen saturation and delivery
Standard concentration	Concentration suitable for most, non-fluid restricted patients
Syringe pump	Small infusion pump. Gradually administer small volume medication or fluid infusions (usually up to maximum 50 mL)
Taper	Gradual reduction or discontinuation of a medication over a specified period or time
Therapeutic drug monitoring	Measurement of medicine (drug) concentration in plasma, serum or blood, to individualise dosage and maintain medicine concentrations within a target range
Titrate	Process of adjusting medication dose – up or down
Train of Four monitoring	Peripheral nerve stimulator used to assess neuromuscular transmission when neuromuscular blocking agents are being administered

Appendix 3: Blank concentration medicines

Blank Concentration Medicines administered by continuous infusion in standard concentrations that additionally require blank concentrations built into Dose Error Reduction Software (DERS). In DERS language a 'blank' concentration is defined as the ability to modify both the amount of medicine, and the volume to individualise a concentration. Blank concentrations are rarely required and should only used in severely fluid restricted patients, or during significant medication shortages. Consultant approval is recommended for the use of any blank concentration for patient safety.

- Acetylcysteine
- Adrenaline (epinephrine)
- · Aminocaproic acid
- Aminophylline
- Amiodarone
- Arginine
- Argipressin
- Atropine
- Bivalirudin
- Botulism immune globulin
- · Calcium chloride
- Calcium gluconate
- Cisatracurium
- Danaparoid
- Desferrioxamine
- Dexmedetomidine
- Dobutamine
- Dopamine

- Epoprostenol
- Esmolol
- Ethacyrinic Acid
- Fentanyl
- Flumazenil
- Furosemide (frusemide)
- Glucagon
- Glyceryl trinitrate
- Hydralazine
- Hydromorphone
- Insulin (ACTRAPID)
- Isoprenaline
- Ketamine
- Labetalol
- Levocarnitine
- Levomepromazine
- Lidocaine (lignocaine)
- Lorazepam

- Magnesium sulfate
- Metaraminol
- Methadone
- Methylene blue
- Metoprolol
- Midazolam
- Milrinone
- Morphine
- Naloxone
- Nesiritide
- Nicardipine
- Noradrenaline (norepinephrine)
- Octreotide
- Omeprazole
- Oxycodone
- Pantoprazole
- Phentolamine

- Phenylephrine
- Pralidoxime
- Procainamide
- Propofol
- Remifentanil
- Rocuronium
- Sodium benzoate
- Sodium bicarbonate
- Sodium nitroprusside
- · Sodium thiosulfate
- Sodium valproate
- Tacrolimus
- Thiopentone
- Tranexemic acid
- Vecuronium

Appendix 4: Authors and acknowledgments

The CIDD team would like to:

- Thank the Queensland Paediatric Critical Care Pathway (QPCCP) project for funding and supporting the CIDD project.
- Acknowledge the support of the Queensland Paediatric Intensive Care Advisory Group (PICAG).
- Acknowledge the generous sharing of knowledge and 'lessons learned' from the 'Children's Resuscitation Emergency Drug Dosage (CREDD)' team/authors.

The CIDD concept and layout have been endorsed by the Children's Health Queensland Medicines Advisory Committee and is suitable to be considered for use at all Queensland Health facilities treating critically unwell paediatric patients.

CIDD steering committee

Executive Sponsor:

 Steven McTaggart – Executive Sponsor, Staff Specialist, Executive Director Medical Services CHQ

CIDD Project Team and Authors:

- Chloe Hall CIDD Clinical Lead, Nurse Educator Children's Critical Care Unit (CCCU) Gold Coast University Hospital (GCUH)
- Quyen Tu Senior Pharmacist, Critical Care, CHQ

- Eloise Lloyd Senior Pharmacist, CCCU GCUH
- Fiona Gregory Pharmacist, Safety and Quality QCH
- Vanessa Muller Pharmacist, ICU Cairns Base Hospital (CBH)
- Sebastian Rimpau Staff Specialist, CCCU GCUH
- Meghan Fitzpatrick Senior Pharmacist, ED Townsville University Hospital (TUH)
- Christian Stocker Director PICU QCH, Medical Co-Lead QPCCP CEQ
- Lilian Tamas Principal Project Officer, QPCCP CEQ

Queensland Paediatric Critical Care Pathways Project:

- Jane Harnischfeger Nurse Educator PICU QCH, CNC QPCCP
- Lynette Adams Project Manager, QPCCP CEQ
- Marcelo Lucha A/Project Support Officer, QPCCP CEQ

Endorsed for state-wide use, with thanks by:

- Paediatric Intensive Care Advisory Group (PICAG)
- Children's Health Queensland Medication Advisory Group (CHQ MAC)
- Queensland Child & Youth Clinical Network (QCYCN) Clinicians' Collaborative

Cairns and Hinterland Hospital and Health Service:

• Tamasine Philp – Pharmacist, Medication Safety CBH

Children's Health Queensland Hospital and Health Service:

- Sonya Stacey Director, Pharmacy CHQ
- Ann-Maree Brady CNC, CHQ Retrieval Service
- Claire Marks Clinical Nurse, PICU QCH
- Melissa Johnson Nurse Educator, CHQ Retrieval Service
- Michele Cree Pharmacist Lead Critical Care, CHQ
- Natalie Tasker Deputy Director, Pharmacy CHQ

Gold Coast Hospital and Health Service:

- Christa Bell CREDD Medical Lead, Paediatric Emergency Physician & Emergency Physician GCUH
- Philip Sargent Director, CCCU GCUH
- Anand Namasivayam CN, CCCU GCUH
- Corrie Bakker CN, CCCU, GCUH
- Dee Jenkins A/NUM, CCCU GCUH
- Karyn Dahms Clinical Pharmacist, GCUH
- Lucie Scott CNC, Children's ED, GCUH
- Nathan Goddard CN, Children's ED, GCUH
- Phillipa Lees RN, CCCU GCUH

Mackay Hospital and Health Service:

 Michael Rampton – Critical Care Educator, ICCU Mackay Base Hospital

Sunshine Coast Hospital and Health Service:

- Lauren Morgan CNC/NUM, Paediatric Critical Care SCUH
- Eleanor Humphreys Pharmacist SCUH
- Elizabeth Upton Pharmacist, Women's and Families Sunshine Coast University Hospital (SCUH)
- Kayla Doyle Pharmacist, Women's and Families SCUH

Townsville Hospital and Health Service:

- Chris Florence Senior Pharmacist, ICU TUH
- Kirsten White CNC, PICU TUH
- Samantha Tenison-Woods Yalurin (Townsville Paediatric Retrieval Service), CNC PICU TUH

